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Diabetes is a rapidly and serious health problem in Scotland. This chronic condition is 
associated with serious long-term complications, including higher risk of heart 
disease and stroke. Aggressive treatment of hypertension and hyperlipideamia can 
result in a substantial reduction in cardiovascular events in patients with diabetes 1. 
Consequently pharmacist-led diabetes cardiovascular risk (DCVR) clinics have been 
established in both primary and secondary care sights in NHS Lothian during the past 
five years. An audit of the pharmaceutical care delivery at the clinics was conducted 
in order to evaluate practice and to standardise the pharmacists’ documentation of 
outcomes.  
Methods 
Pharmaceutical care issues (PCI) and patient details were collected both 
prospectively and retrospectively from three DCVR clinics. The PCI`s were 
categorised according to a triangularised system consisting of multiple categories. 
These were ‘checks’, ‘changes’ (‘change in drug therapy process’ and ‘change in 
drug therapy’), ‘drug therapy problems’ and ‘quality assurance descriptors’ (‘timer 
perspective’ and ‘degree of change’). A verified medication assessment tool (MAT) 
for patients with chronic cardiovascular disease was applied to the patients from one 
of the clinics. The tool was used to quantify PCI`s and pharmacist actions that were 
centred on implementing or enforcing clinical guideline standards. A database was 
developed to be used as an assessment tool and to standardise the documentation 
of achievement of outcomes. Feedback on the audit of the pharmaceutical care 
delivery and the database was received from the DCVR clinic pharmacist at a focus 
group meeting.  
Results 
For the 47 study patients ( 44.7% male, 85.1% type 2 diabetes mellitus) mean (SD) 
age was 65.7 (12.6) years and mean (SD) time since diagnosis of diabetes was 14.9 
(8.9) years. Overall number of identified care issues was 727 with mean (SD) 3.91 
(1.27) care issues per care episode. Of the total care issues, 373 (51.3%) were 
‘checks’, 211 (29.0%) were ‘changes in drug therapy process’ and 147 (19.7%) were 
‘changes in drug therapy’ and an identified ‘drug therapy problem’ (DTP). Of the 
checks, 519 (88.9%) were ‘monitoring’ checks, while all changes, 143 (100%), were 
‘adjustments’. The number of patients included in the application of the MAT 
guideline standards was 33. A total of 51 care issues leading to a change in the 
medication was identified and resulted in 130 guideline standards that were directing 
the goal of the medication change. 
Conclusion 
The results from the audit showed that the pharmacist made a major contribution to 
ensure effective and safe treatment for the patients and optimising drug doses. Lack 
of pharmacist documentation was the reason for discrepancy from practice in some 
areas of the pharmaceutical care delivery. A database would help to standardise the 
documentation of pharmacist actions and identification of pharmaceutical care 
issues. Further refinement of the tool will likely improve the ease of use and minimise 
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1.1 Pharmaceutical care 
1.1.1 The concept of pharmaceutical care 
Pharmaceutical care has been defined by Hepler and Strand in 1990, as “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient’s quality of life. These outcomes are (1) cure of disease, (2) 
elimination or reduction of a patient’s symptomatology, (3) arresting or slowing of a 
disease process, or (4) preventing a disease or symptomatology” 2. The word 
‘pharmacist’ is not part of the definition. Pharmaceutical care can therefore be 
regarded as achievable through the performances of a team of healthcare 
professionals, including pharmacists, but also including technicians, doctors and 
nurses. It also enables pharmaceutical care to be delivered in different ways, in 
different clinical settings e.g. hospital wards, primary care settings and community 
pharmacies. The concept of pharmaceutical care is therefore a description of what 
the patient should receive and not what the pharmacist does 3. It is this model which 
has been mainly used and adapted within the UK to shape the delivery of pharmacy 
practice and the delivery of pharmaceutical care. 
 
Cipolle et al later refined Hepler and Strand’s philosophy of pharmaceutical care to 
be defined as a patient-centred practice 4. In both these definitions the emphasis is 
on the patient and the pharmacist’s responsibility to ensure good quality of the care 
they provide to the patient and to achieve better patient outcomes.  
 
The pharmacist’s role has evolved over the twentieth century from mainly being 
product focused, preparing and dispensing drugs, into a more patient –orientated 
care provider, and pharmaceutical care may be the target for the pharmacy 
profession world-wide.  
 
Even though pharmaceutical care is delivered by many different healthcare 
professionals, the pharmacists can be regarded as specialists in this practice as their 
focus is on pharmacology and pharmacotherapy, important skills to provide 
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pharmaceutical care. The need for a practitioner focused on drug therapy has 
become urgent, since the responsibilities associated with drug therapy have become 
numerous and complex. A pharmacist has the possibility to focus on pharmaceutical 
care on a full-time basis, and is therefore expected to take the primary role as the 
pharmaceutical care provider. However, it is important that the pharmaceutical care 
practitioners understand each patient’s medication experience better than all other 
healthcare professionals, only then is it possible to have a positive impact on the 
patients decisions and experiences with their drug therapy. The patient’s medical 
experience includes patient’s expectations, wants, concerns, preferences, attitudes, 
and beliefs, as well as the cultural, ethical, and religious influences on his/her 
medication taking behaviour. It is the pharmacist’s primary role to optimise this 
experience. Only when a patient’s medication experience is known and understood 
can the pharmacist successfully take on the responsibilities of identifying, resolving 
and preventing drug-therapy problems. As a result the patient understands and 
achieves the desired therapeutic goal for each medical condition being treated. 5 
 
Since the pharmacist is part of the multidisciplinary team which delivers 
pharmaceutical care to the patient, it is important that they share a common 
vocabulary. This facilitates good communication between the different members of 
the healthcare team and continuity of care.4 
 
 “The Right Medicine” 6 is the Scottish Executive strategy (2002-2005) for pharmacy, 
both for hospital pharmacy services and community pharmacies. It outlined how 
pharmacists can contribute to improve services to the public and to patients, by better 
utilising their skills within the use of medicines. The strategy also supports 
pharmacists in their work with helping patients get the maximum benefit from their 
medicines and shows where action has to be taken to achieve that goal. It 
highlighted the need to modernise and strengthen pharmacists’ education and 
training, to ensure patients’ receive professional standards of the care. A systematic 
approach in the delivery of pharmaceutical care ensures that the patient gets “the 
right medicines, in the right dose, at the right time and for the right reasons” 6. 
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1.1.2 Documentation in pharmaceutical care 
Continuity of pharmaceutical care depends on good communication between 
healthcare professionals, which in turn depends on reliable records. All practitioners 
are required to document the care they provide. Pharmacists have developed their 
own ways of documenting the information necessary to carry out their part in the care 
of the patient. The Pharmaceutical Care Plan is extensively used within the UK. 
These care plans are used to organise each patient’s identified goals of therapy, 
interventions to resolve drug therapy problems, how to achieve goals of therapy and 
to prevent new drug therapy problems from developing. Every intervention made by 
the pharmacist should be documented, and is best done at the time the patient is 
seen by the pharmacist or shortly thereafter. A valid documentation system is 
necessary to justify decisions made regarding the patients treatment plan and to 
evaluate outcomes 4. Standardised pharmaceutical care plans used to document 
pharmaceutical care issues would be useful to standardise the provision of care to 
different patient groups. Work in this area has been done in Scotland in the provision 
of pharmaceutical care to cancer patients receiving chemotherapy 7. 
 
The use of electronic documentation systems is much more effective and efficient 
than a paper system. Development of an electronic hand-held pharmaceutical care 
plan would facilitate prospective data capture at the patient’s bedside 7. The data 
entered in a database are better standardised and would help to generate a more 
consistent delivery of care. The information needs only to be entered into the 
database once and reports could be generated to assess the delivery of 
pharmaceutical care 4. 
 
1.1.3 Pharmaceutical care for patients with diabetes 
There are an ever increasing number of people with diabetes and long-term 
conditions in Scotland 8. The complexity of the condition clearly points out the need 
for support from a variety of healthcare professionals in the delivery of 
pharmaceutical care, such as the clinician supervising treatment, diabetes specialist 
nurse, GP, dietician, podiatrist, community pharmacist, consultant and 
ophthalmologist 9. In Scotland, the Scottish Executive has published the “Scottish 
Diabetes Framework Action Plan” 8, which acknowledges the burden of diabetes on 
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Society and aims to raise standards of diabetes care in Scotland. It calls attention to 
the need to facilitate self-management and delivery of services closer to the patient, 
by expanding community pharmacists’ roles and integrating them into the 
multidisciplinary team.  
 
It is estimated that 600 000 people across Scotland visit their local community 
pharmacy every day 6. The community pharmacy is often the first point of call for 
people with newly diagnosed diabetes, and the community pharmacist is in a position 
to deliver pharmaceutical care, rather than solely supplying medicine 9. With 
pharmacists’ prescribing rights being extended from supplementary prescribers to 
independent prescribers 10, this could open new doors to greater opportunities in the 
delivery of pharmaceutical care. The new community pharmacy contract that is being 
introduced in Scotland includes a chronic medication service, giving pharmacists 
increased responsibility in providing pharmaceutical care to patients with long term 
conditions, including diabetes 11. Pharmaceutical care services for diabetes patients 
are developing in Scotland although these are not consistent 12. 
 
Pharmaceutical care is very difficult to evaluate because of its complexity, and the 
amount of published work is therefore limited 13. There is little known about the 
feasibility and impact of the community pharmacist input in the multidisciplinary team 
in both primary and secondary health care settings 14. One pilot study, of the 
integration of the community pharmacist in the healthcare team, showed that 
pharmacist are effective and well accepted by GP`s and patients 14. During the study 
period the pharmacist supported patients by giving medication advice to improve 
patient understanding of their medicines and also collaborated with physicians to 
optimise the pharmacological management of glycaemia, hypertension and 
dyslipidaemia in patients with type 2 diabetes. The patients had an initial and final 
assessment where the main outcome measures were HbA1c, blood pressure, lipid 
profile and medication compliance. Over the study period a reduction in all biological 
measures was observed and patients’ knowledge of their medication improved. No 




Three other studies 15-17 have shown that pharmacist-led clinics have a positive 
impact on cardiovascular risk factors, like blood pressure, hyperlipidaemia and 
glycaemic control for patients with type 2 diabetes and consequently on their risk of 
cardiovascular disease. The patients in these studies were seen by the clinic 
pharmacist every 4-8 weeks, where necessary adjustments to their treatment were 
made. This aggressive approach to optimise patients’ treatment led to a reduction in 
blood pressure, lipid levels and HbA1c. One of the studies also assessed the cost-
effectiveness of such a model and found it comparable to other healthcare 
interventions 16. 
 
1.2 Diabetes mellitus 
 
Diabetes mellitus is a chronic metabolic disease characterised by disorders in 
carbohydrate, fat and protein metabolism and resulting hyperglycaemia. 
Hyperglycaemia is caused by defects in insulin secretion, insulin action or both. Over 
time chronic hyperglycaemia can lead to severe long-term complications, affecting 
several organ systems. Abnormalities in insulin secretion and insulin action occur due 
to several pathogenic processes, which range from autoimmune destruction of 
pancreatic β-cells to abnormalities that result in resistance to insulin action. 
 
There are several different categorises of diabetes according to the underlying 
etiologic cause of the disorder. Most cases of diabetes mellitus fall into two main 
categorises: type 1 diabetes and type 2 diabetes. Another common type of diabetes 
is gestational diabetes mellitus (GDM) which refers to glucose intolerance first 
recognised during pregnancy. 18, 19 
 
1.2.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus is recognised by an absolute deficiency of insulin resulting 
from immune-mediated destruction of the β-cells of the pancreas. Only 5 to 10% of 
people with diabetes fall into this category previously know as insulin-dependent 
diabetes mellitus (IDDM) or juvenile-onset diabetes. It usually presents in early 
childhood and has a peak incidence around puberty, however it can present at any 
age.  
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The autoimmune destruction of the β-cells is related to multiple genetic 
predispositions and environmental factors that are still poorly defined. The rate of β-
cells destruction is quite variable and the patient becomes overly diabetic only when 
more than 90% of the β-cells have been destroyed 20. Onset of the disease is in most 
cases abrupt and may present with ketoacidosis as the first manifestation of the 
disease. The patient also typically presents with all of the classical symptoms: 
polydipsia, polyuria, polyphagia, weakness, weight loss and dry skin, which makes it 
easy to diagnose. The majority of these patients require insulin for survival, even 
though some patients may briefly return to normoglycaemia. 18, 19 
 
1.2.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus is the most common type of diabetes. It is responsible to 
approximately 90 to 95% of all cases. This form of diabetes was previously referred 
to as non-insulin dependent diabetes (NIDDM) or maturity onset diabetes. The main 
characteristics of type 2 diabetes are impaired insulin secretion and some degree of 
insulin resistance of target tissues, primarily the liver and skeletal muscle. Many 
patients therefore have normal to elevated levels of insulin, due to increased 
secretion of insulin in an attempt to compensate for the diminished activity of insulin. 
Despite this blood glucose levels rise due to the insulin resistance. These 
pathological and functional changes may be present over a long period of time 
without any clinical symptoms before diabetes is detected. Such patients are at 
increased risk of developing macrovascular and microvascular complications. 19-21 
 
Typically type 2 patients are over 40 years of age and most of them are obese, and 
obesity itself causes some degree of insulin resistance. Weight loss and or/ oral 
hypoglycaemic drugs may improve insulin resistance. The risk of developing this form 
of diabetes increases with age, obesity and lack of physical activity. Today there are 
an increasing number of people in younger age groups with type 2 diabetes due to 
obesity and sedentary lifestyle 22. The International Diabetes Federation (IDF) has 
stated that up to 80 % of type 2 diabetes is preventable by adopting a healthy 
lifestyle, in terms of nutrition, physical activity and ideal body weight.23  
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1.2.3 Epidemiology of diabetes mellitus 
Prevalence of diabetes world wide 
Diabetes is a serious condition not only for the individual, but for Society as a whole. 
It currently affects 246 million people world-wide and this number is expected to 
increase to 380 million by 2025 23. Developed countries have a higher prevalence of 
diabetes than developing countries, but the increase of people with diabetes is 
projected to increase in both. Developing countries will be hit the hardest by the 
growing diabetes epidemic. An aging population, a shift towards a more sedentary 
lifestyle, increasing numbers of overweight and obese people and unhealthy diet are 
possible factors contributing to this alarming increase of diabetes prevalence. 
Growing urbanisation is also believed to be a possible contributing factor to the 
problem. According to the International Diabetes Federation, the five countries with 
the highest diabetes prevalence in 2007 are Nauru (30.7%), United Arab Emirates 
(19.5%), Saudi Arabia (16.7%), Bahrain (15.2%) and Kuwait (14.4%) 24. 
 
Prevalence of diabetes in the United Kingdom (UK) and Scotland 
In the annual 2005 Scottish Diabetes Survey, more than 170 000 people were 
identified from data submitted by all the NHS Boards, which represents 3.4% of the 
Scottish population. Nearly half of those patients identified were aged 65 years or 
more, and more than 80% had type 2 diabetes 25. Within 25 years it is assumed that 
as many as one in 10 people in Scotland will have diabetes 8. UK prevalence for 
diagnosed diabetes has been estimated to be in the region of 1.8 million people or 
approximately 3% of the population. As many as 765 000 to 1 million people in the 
UK are suspected of having undiagnosed type 2 diabetes 22. 
 
Ethnicity is also linked to diabetes. It has been shown in the UK that certain ethnic 
minority groups are more likely to develop type 2 diabetes than the indigenous 
population, to develop it earlier and present with its complications. This is particularly 
evident in South Asians, but also in people from African and Caribbean backgrounds. 
In these communities the prevalence of diabetes is at least five times higher or more. 
If we compare these two ethnic communities with the whole UK population, the 
prevalence of diabetes in South Asians and Afro-Caribbean’s, are 20% and 17%, 
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respectively, in contrast to the prevalence of three percent in the UK population as a 
whole. 22, 26 
 
1.2.4 Diabetic complications 
Diabetes is associated with serious long-term effects which could have a huge impact 
on the quality of life of patients, especially when both microvascular and 
macrovascular complications are present. The risk factors for developing 
microvascular complications include; duration of diabetes, glycaemic control and 
hypertension, whilst the strongest risk factors for the development of macrovascular 
complications include hypertension, hyperlipidaemia, smoking and albuminuria. 
Figure 1 27 illustrates the factors contributing to cardiometabolic risk. 
 
 
Figure 1. Factors contributing to cardiometabolic risk 
 
Microvascular complications affect the small blood vessels and comprise of 
retinopathy, nephropathy and neuropathy. Macrovascular complications encompass 
cerebrovascular disease, ischemic heart disease and peripheral arterial disease 28. 
 
The risk for macrovascular diseases tend to manifest in people with type 2 diabetes 
more than those diagnosed with type 1 diabetes, and as hyperglycaemia contributes 
to the development of these complications, studies have proved the relationship 
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between the degree of glycaemic control and the development of these complications 
29. The first goal in the management of both type 1 and type 2 diabetes is therefore 
management of hyperglycaemia. 
 
Two trials, The Diabetes Control and Complications Trial (DCCT) 30 and the United 
Kingdom Prospective Diabetes study (UKPDS) 1, have both confirmed the benefit of 
tight glycaemic and blood pressure control on the reduction of long term 
complications. In the UKPDS study, the group assigned to tight blood pressure 
control showed a 37% reduction in incidence of microvascular complications and 
significant reduction in risk of 24% for any endpoint related to diabetes 1. 
 
 
1.3 Guideline recommendation for primary and secondary 
prevention of cardiovascular disease with main focus on diabetes 
 
Guidelines exist locally in Scotland developed by Scottish Intercollegiate Guideline 
Network (SIGN). These are evidence-based clinical guidelines derived from a 
systematic review of the scientific literature. For the prevention of cardiovascular 
diseases revised guidelines were published in February 2007 31. There is also a 
guideline for the management of diabetes, SIGN 55 32, which is currently under 
review and new guidelines are imminent.  
 
To reduce cardiovascular risk, both guidelines emphasise the importance of: 
 
• Diet by altering dietary fat intake and reducing dietary salt – which could help 
to lower blood pressure; and increase fruit and vegetable intake 
 
• Encouraging people to increase their activity level 
 
• Giving advice and help on how to stop smoking 
• Moderate alcohol intake  
 
There are three main focus areas on the pharmacological treatment of the primary 
and secondary prevention of cardiovascular disease: (1) antiplatelet therapy, (2) lipid 
lowering therapy and (3) blood pressure lowering. 
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1.3.1 Antiplatelet therapy 
In the secondary prevention of cardiovascular disease the use of aspirin is well 
established. A low dose of aspirin at 75 mg is indicated for all individuals with 
established atherosclerotic disease. The benefit of using low dose of antiplatelet 
therapy is that it reduces the risk of gastrointestinal bleeding compared to higher 
doses. There is no clinical evidence to support long-term treatment, but the perceived 
benefit of treatment means life-long treatment with aspirin is usual. Individuals with a 
history of stroke or transient ischemic attack (TIA) should also have a low dose of 
aspirin in addition to dipyridamole (200 mg twice daily). In both situations, people who 
have an intolerance or hypersensitivity to aspirin or where aspirin causes 
unacceptable side-effects, clopidogrel should be considered as an alternative. 
 
In the primary prevention of cardiovascular disease, in asymptomatic individuals with 
no established atherosclerotic disease, but whose estimated CVD risk is ≥ 20% over 
ten years, should be considered for aspirin therapy.31  
 
In the use of aspirin in the primary prevention of cardiovascular disease among 
people with diabetes, there are few data. The guideline recommends aspirin 75 mg 
daily for all patients with diabetes type 2 who are older than 50 years of age, and also 
in younger individuals with diabetes believed to have a high cardiovascular risk.31, 32 
 
People with hypertension should be treated with aspirin if their 10 year risk of 
cardiovascular disease is above 20%, and only if their blood pressure is well 
controlled and treated to <150/90 mmHg. The blood pressure has to be under that 
level to reduce the risk of cerebral haemorrhage.31  
 
1.3.2 Lipid lowering therapy 
The use of statins (HMG-CoA reductase inhibitors) is central to lipid lowering therapy 
in both primary and secondary prevention of vascular events. Their primary action is 
to reduce LDL cholesterol, and only small reductions in HDL cholesterol and 
triglyceride levels.  
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For individuals with high cardiovascular risk, the use of simvastatin 40 mg/day is 
indicated and considered to be used in treatment of all adults > 40 years of age with 
an estimated ten year CVD risk over 20% 31. In people with diabetes type 2 without 
evidence of nephropathy with CVD risk ≥30%, lipid-lowering therapy should be 
considered as the same as for non-diabetics 32. For patients with type 1 diabetes and 
patients with type 2 diabetes and nephropathy, the current assessment methods may 
underestimate the cardiovascular risk. In these individuals lipid-lowering therapy 
should be considered at a lower risk threshold 32. 
 
The existing target for total cholesterol < 5 mmol/l in individuals with established 
symptomatic cardiovascular disease, should only be regarded as the minimum 
standard of care 31. This is also the treatment goal for individuals with diabetes 32. 
 
In people who do not tolerate higher doses of statin, the use of a standard statin dose 
in combination with an anion exchange resin or ezetimibe should be considered. 
Other lipid lowering agents, like a fibrate or a nicotinic acid, should be used in 
individuals with hypertriglyceridaemia (>1.7 mmol/l) and/or low HDL cholesterol level 
(< 1 mmol/ l in men and < 1.2 mmol/l in women).  
 
Combined dyslipidaemia is particularly characteristic of the metabolic syndrome and 
in diabetes mellitus. This condition is characterised by elevated plasma triglycerides, 
low HDL cholesterol and smaller, denser and more atherogenic LDL particles than 
normal. This condition is associated with an even greater risk of cardiovascular 
events, than when only LDL cholesterol is raised. The use of a statin is the drug of 
choice in this condition, and in some cases a combination with a fibrate is 
necessary.31 
 
1.3.3 Blood pressure lowering therapy 
Blood pressure lowering therapy should be considered for individuals with 
established cardiovascular disease or with ten year CVD risk > 20%, and who has 
sustained blood pressure >140 mmHg systolic and/or diastolic blood pressure > 90 
mmHg. In these individuals the target blood pressure is <140/85 mmHg 31. In 
individuals with diabetes without any complications, diastolic blood pressure should 
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be reduced further to 80 mmHg 32. For individuals with established cardiovascular 
disease and who also have diabetes with complications (e.g. nephropathy) or chronic 
renal disease or target organ damage, the limit for initiation of blood pressure therapy 
is >130 mmHg systolic and/or > 80 mmHg diastolic. Target blood pressure in this 
group is <130/80 mmHg.  
 
There are four major classes of antihypertensive agent: (1) thiazides, (2) angiotensin 
converting enzymes (ACE) inhibitors, (3) angiotensin-II-receptor antagonists (ARB) 
and (4) calcium channels blockers. Beta-blockers are also used in treatment of 
hypertension, but is regarded as being less effective than the other four groups.31 
 
In the treatment of hypertension the use of two or more than two antihypertensive 
agents, in half to standard doses, is often considered to achieve additive blood 
pressure lowering effect and to reduce the adverse effect profile. 
 
The British Hypertension Society (BHS) AB/CD algorithm for blood pressure 
incorporates all classes of antihypertensive drugs, and is widely accepted for 
deciding drug therapy for the individual. In June 2006, NICE (The National Institute 
for Health and Clinical Excellence) and BHS released a new revised guideline with 
updated clinical evidence and a cost-effectiveness analysis 31. The new 
recommendations based on this evidence are summarised in the A/CD algorithm 31 in 




Figure 2. British Hypertension Society A/CD algorithm for blood pressure 
 
In patients with diabetes, an ACE-inhibitor should be given to individuals >55 years of 
age, and who also smoke, have total cholesterol > 5.2 mmol/l, HDL cholesterol ≤ 0.9 
mmol/l, microalbuminuria, proteinuria or hypertension. The use of ACE-inhibitors is 
also indicated in diabetic patients who have had a myocardial infarction (MI) and/or 
heart failure due to left ventricular dysfunction.32 
 
In the case of significant bilateral renal artery stenosis, ACE-inhibitors are 
contraindicated because it is associated with acute renal failure.32 
 
Following MI patients should be prescribed long-term treatment with a beta-blocker 33 
and diabetes is not considered to be a contraindication for use of this class of 
antihypertensive drug 32. Beta-blockers are also considered as first line treatment for 
the relief of symptoms of stable angina – and should therefore be used in secondary 
prevention of cardiovascular disease 34. 
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1.4 Clinical audit 
 
The goal for all NHS health care professionals is to improve the quality of patient care 
and to continue to improve; clinical audit is the method believed to provide the 
framework in which this can be done. Clinical audit can be defined as 35: “a quality 
improvement process that seeks to improve patient care and outcomes through 
systematic review of care against explicit criteria and the implementation of change”. 
Clinical audits are therefore a method which can be used to provide evidence on 
current practice against guideline standards (i.e. SIGN) or quality improvement 
standards defined by NHS Quality Improvement Scotland. It can provide information 
about the structures, the process or outcomes of a health care service and also serve 
as a check concerning: “Are we actually doing what we think we are doing?” Finally, 
clinical audits can provide evidence on the quality of care delivered in a service. This 
enables stakeholders like, other staff, carers, patients and management to have 
confidence in the quality of care that is provided. 36 
 
In 1996-1997 clinical audit was integrated in clinical government systems, and by 
1998 full participation off all hospital doctors was made an explicit component of this 
system. After this, in 2000, “The NHS Plan” 37 took it one step further and supported 
the involvement of other staff members, including nurses and midwives. In a report 
by the “Bristol Royal Infirmary Inquiry” 38 , which followed excess deaths associated 
with paediatric surgery and linked to questions about competence of practitioners, 
several recommendations were made. The recommendations that are especially 
interesting are 35: 
  
•  “The process of clinical audit, which is now widely practised within trusts, 
should be at the core of a system of local monitoring of performance”. 
 
• “Clinical audit must be fully supported by trusts. They should ensure that 
healthcare professionals have access to the necessary time, facilities, 
advice and expertise in order to conduct audit effectively. All trusts should 
have a central clinical audit office that coordinates audit activity, provides 
advice and support for the audit process, and brings together the results of 
audit for the trust as a whole”. 
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•  “Clinical audit should be compulsory for all healthcare professionals 
providing clinical care and the requirement to participate in it should be 
included as part of the contract employment”. 
 
Clinical audit can be viewed as a cyclical process (figure 3 36), where the cycle is 
divided into different stages. The stages follow a systematic process of establishing 
best practice, measuring against criteria, taking actions to improve care, and 
monitoring to sustain care. As the process continues, each cycle can be regarded as 
trying to reach a higher level of quality. In order to execute a successful clinical audit, 
the methods used should be well understood and the organisational environment has 











A clinical audit can be divided into five steps 35:  
• Preparing for audit 
• Selecting criteria 
• Measuring performance 
• Making improvements 
• Sustaining improvements 
 
Good preparation is crucial to the success of an audit. The first thing that needs to be 
done is selection of a topic. In the decision making of this process participating staff 
could be used, but is not necessary. Participation could however have an important 
role in creating the necessary supportive environment that is needed. The topics 
selected are priorities within a given service, and an audit is conducted with the 
means of improving the service provided to the users of that care, or to confirm that 
current practice meets the expected level of performance. Healthcare members 
involved have to have the skills to execute the audit and must be given enough time 
to participate fully in the project. 35 
 
For the selected criteria to be valid and lead to improvement in the quality of care, the 
criteria should be based on evidence, relate to important aspects of care and be 
measurable. To achieve this, explicit rather than implicit criteria are preferred to give 
a more reliable audit. This means that one should study for specific, detailed part of 
the care. The specification of appropriate care should be done by referring to 
recommendations in clinical guidelines. Clinical guidelines are based on review of 
relevant research evidence, and the criteria are therefore likely to be valid. Both the 
process and the outcome can be used in the assessment of clinical audits. The 
choice however depends on the topic and objectives of the audit. Measurement of 
outcomes can for example be used to identify problems with care, and is often the 
method of choice when the outcome is clear. 35  
 
In order to measure performance, patients have to be identified. Patient registers are 
used in this process. Clinical records are frequently used to gather necessary data. 
Such records are often incomplete and several sources may have to be used to 
collect the data. However an audit could also be used as a method of improving 
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documentation, which is of great importance in the quality of care of patients. If 
routinely collected data are available, they may be appropriate for use in an audit and 
makes the whole process much easier. Another way of getting information is to use 
sheets recorded by the healthcare provider at the time of delivery of care. Various 
statistical methods are used to analyse the audit data. 35 
 
The data collected are compared with criteria and standards, and the outcome of the 
audit are used to draw conclusions on how well the standards are met or identifying 
reasons for why the standard are not met in all cases. In the end, an audit will 
therefore result in some sort of change in practice in order to make improvements for 
the future. After some time, when changes have been implemented the audit cycle 
usually should be repeated in order to assess if the proposed change have been put 
in practice and improvements are seen. 35   
 
 
1.5 Project focus 
 
Evaluating pharmaceutical care is difficult. The process of pharmaceutical care is 
multi-factorial and involves many different healthcare providers. It is therefore difficult 
to attribute any change in outcome solely from the contribution of the pharmacist. The 
thought process and actions performed by the pharmacists while providing 
pharmaceutical care is also not easy to measure. A defined standardised way of 
achieving just that is therefore sought after. Categorisation of drug related 
pharmaceutical care issues is a way to put the pharmacists input into a system. 
Profiles like these can be used to compare clinical settings and evaluate services. 
Such profiles can provide the evidence of the added benefit of integrating 
pharmacists into the multidisciplinary team. As policy makers and higher 
management contemplate reimbursement of pharmacist services it is necessary for 
pharmacists to prove their worth. An important tool used in this process would be 
increased use of standardised documentation systems integrating evidence-based 
clinical guidelines. By transferring current paper systems over to computer-based 
systems the standard of documentation would be increased further.  
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The focus of this project was to evaluate the pharmaceutical care delivery to patients 
attending the DCVR clinics. A previous study of one of the pharmacists 
pharmaceutical care activities resulted in production of a pharmaceutical care plan 
incorporating clinical guidelines 39. The incorporation of guideline standards in the 
pharmaceutical care plan would facilitate the quality of prescribing as routine practice 
and provide continuous quality monitoring. The pharmaceutical care plan has now 
been implemented in some of the clinics. There is now a need to extend the 
implementation to other sites and for a continuous audit of practice. A profile of the 
pharmaceutical care provided by three chosen clinics will be produced. The project 
will also result in a database suitable to record clinical outcomes and pharmaceutical 
care issues addressed by the pharmacists. The database will facilitate the recording 
of achievement of outcomes and serve as an assessment tool in further practice. 
 
1.5.1 Diabetes Cardiovascular Risk Clinics, Lothian 
Pharmacist-led clinics have been established within both primary and secondary care 
sites in NHS Lothian since 2003. These have achieved significant reductions in 
patients’ blood pressure (mean 34 ± 17 mmHg systolic and 16 ± 11 mmHg diastolic) 
and improved lipid profiles 17. The patients are referred to the clinic from the general 
diabetes clinic. Referral criteria are broad, but the clinics are primarily aimed to 
patients not achieving target blood pressure and/or lipid profile and with high 
cardiovascular risk. In a busy diabetes clinic correct blood pressure monitoring is 
difficult due to time constraints, which could lead to reluctance to recommend 
treatment 40. A closer follow-up at a pharmacist-led clinic could be beneficial to 
reduce cardiovascular risk.  
 
At the clinic the pharmacists 17: 
• Measure blood pressure, including the use of ambulatory 24-hour monitors 
 
• Review the patient cardiovascular medication in accordance with a treatment 
protocol based on SIGN guideline 55. 
 
• Review lipid profiles  
 
• Subjectively assess patients compliance with medication 
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• Take blood and urine samples to monitor the effect of patients medication on 
their U & E and LFT consentrations 
 
• Assess body weight, smoking status and exercise level, and provide advice on 
adoption of a healthy lifestyle. When appropriate referrals are made to a clinic 
dietician or a smoking cessation facilitator 
 
• Play a role in achieving compliance and concordance with the patient. 
 
After each clinic the pharmacist discusses each case with the consultant responsible 
for the clinic, before making written treatment recommendations to their GP. Patients 
GP and/or community pharmacist are frequently contacted to check compliance. 
 
A recent study showed that patients previously thought to be “resistant” to treatment 
had a significant reduction in cardiovascular risk factor targets when attending an 
intense clinical setting 40. Patients previously attending one of the DCVR clinics were 
followed up at least six months after discharge to determine the efficacy and long-
term effect of the interventions. The study showed that improvement in blood 
pressure and total cholesterol level was sustained after discharge 40. 
 
 
1.6 Focus group 
 
Focus groups interviews are a form of qualitative research methodology used to 
generate data on a specific topic 41. The interview has the form of a discussion with a 
selected group of individuals and the researcher, to gain information about their 
views and experiences on the selected topic. This approach enables the researcher 
to obtain a larger amount of information over a shorter period of time compared to 
individual interviews 42. Group discussions can also make it easier for people to 
explore and clarify their views in ways that would be less easy in a face-to-face 
interview. The interviewer usually presents a series of open-ended questions with the 
intention to encourage the participants to explore the issues of importance to them, 
generating their own questions and pursuing their own priorities. Using focus groups 
makes it impossible to identify the views of individuals from the group view, since 
they are expressing their opinions in a specific context 42.  
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The person conducting the interview has a two part role. His or her responsibility is to 
moderate by keeping the discussion focused and if necessary steer the discussion 
back on course. The other role is to function as a facilitator to ensure that the group 
runs effectively 42, 43. These are not easy tasks and call for good leadership and 
considerable skill and experience in order to be done well. Focus groups interviews 
typically extend over at least an hour, possibly two. Usually the person running the 
focus group has another person helping with taking detailed notes, administering the 
tape-recorder and helping in handling unexpected interruptions and asking questions 
where important and relevant.43  
 
1.6.1 Group composition 
Typically the focus group is composed of six to ten individuals, but it can have as few 
as four or as many as 15 people. The group has to be small enough so that everyone 
gets a chance to express their opinion, but large enough so that the group comprises 
participants with different perceptions. The group can be composed in two ways, as a 
homogenous group or as a heterogeneous group. Most researchers recommend 
aiming for a homogenous group 41. In a homogenous group the participants have a 
common background, position or experience and could also often be “naturally 
occurring”, for example consist of people who work together. This facilitates 
communication, promotes an exchange of ideas and experiences and also gives a 
sense of safety in expressing their own views. However, homogenous group can also 
result in “group think”, so that diverse opinions and experiences may not be 
revealed.41-43 
 
In a heterogeneous group, where the participants have a different background, 
position and experience, these differences can stimulate and enrich the discussion. It 
can also inspire the other group members to look at a topic in a different light. Some 
of the disadvantages with a heterogeneous group are the risk of power imbalances 
within the group, which can affect who speaks and what they say. It can also lead to 
lack of respect for the opinions expressed by some members of the group. A 
particular problem arises when one or two persons dominate the group, which can 
destroy the group process. This phenomenon is not only restricted to heterogeneous 
group, but can also be a problem in homogeneous groups. 41, 43 
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1.6.2 Advantages and disadvantages 
There are several advantages in the use of focus group interviews. It enables the 
researcher to collect data from several people at the same time, and is therefore both 
an effective and inexpensive research method. Group dynamics help in focusing on 
the most important topics and extreme views tend to be held under some control 
because the participants will often check and control each other. The rest of the 
group can also encourage people who normally do not express their own opinion, 
because they feel they have nothing to say, to do so. The participants can express 
their views in their own words, and the method therefore does not discriminate 
against people who cannot read or write. Participants tend to enjoy the experience, 
and they are also stimulated by thoughts and comments of others in the group.  
 
Use of focus groups also has disadvantages. Due to the limited amount of time, the 
number of questions that can be asked are limited. Typically fewer than 10 questions 
can be asked in an hour. If one or two people dominate the group, the results can be 
biased by their view. The discussion therefore needs to be well managed and this 
requires considerable skills. Another disadvantage is that the results cannot be 
regarded as representative for the wider population, and therefore cannot be 
generalised.  Confidentiality can be a problem in “group settings” and the participants 
need to be encouraged to keep confidential what they hear under the meeting. The 





2 Aim and objectives 
 
2.1 Aim 
• Evaluate practice within pharmacist-led Diabetes Cardiovascular Risk Clinics 
and identify benefits from implementation of a standardised pharmaceutical 
care plan. 
• Develop a database tool for reporting pharmaceutical care needs and actions 
for wider application in pharmacist-led Diabetes Cardiovascular Risk clinics 
and pharmacist-led Diabetes Management clinics. 
 
2.2 Objectives 
1. Review the literature on models of pharmaceutical care to patients with 
diabetes. Review documentation from local services to characterise 
service provision in hospital and primary care settings. 
 
2. Conduct a prospective and retrospective audit of pharmaceutical care 
episodes at three chosen clinics. Quantify guideline standards 
addressed by the pharmaceutical care issues identified by the 
pharmacist at the clinic located at Western General Hospital. 
 
3. Develop and populate a database using pharmaceutical care data from 
three chosen sites to quantify the pharmaceutical care issues 
addressed by the pharmacists and to standardise the recording of 
achievement of outcomes. Ensure that the database is suitable for 
recording data from pharmacist-led Diabetes Cardiovascular Risk 
(DCVR) risk clinics and pharmacist-led Diabetes Management clinics. 
 
4. Receive feedback from a focus group of the DCVR clinic pharmacists to 
identify opportunities to standardise the approach of the pharmacists 
and the audit tools. 
 36 
 37 
3 Subjects and Settings 
 
The setting was three chosen outpatient Diabetes Cardiovascular Risk Clinics 
(DCVR) in Edinburgh located at Western General Hospital, Royal Infirmary of 
Edinburgh and Leith Community Treatment Centre. The three clinics will be referred 
to as clinic A, B and C, respectively hereafter. Clinics A and B are run on a weekly 
basis, while clinic C runs every fourth week. Patients are referred to the clinic by the 
Diabetes Clinic consultant physicians when they are considered to have high 
cardiovascular risk, and need a closer follow-up of their blood pressure and/or lipid 
profile. The pharmacists have the capacity to see six patients every clinic day, and 
the patients are asked to attend the clinic every 6-8 weeks.  
 
For the purpose of this study, the researcher sat in at the three different clinics and 
collected patient details and pharmaceutical care issues prospectively. For patients 
previously seen by the pharmacist, the researcher also collected pharmaceutical care 
issues addressed by the pharmacists retrospectively. The data collection period was 
from February 5th until March 19th. A total number of 35 patients were seen by the 
pharmacists during this period. This patient sample reflects an opportunistic sample 
of patients under current care at the time the researcher visited the clinics. Of the 35 
patients, three were new patients (two patients from clinic A, including one patient 
who was previously discharged from the clinic, and one patient from clinic B).  
 
From clinic A, the researcher also retrospectively collected pharmaceutical care 
issues on a random selection of patients under current care (6 patients) and 
previously discharged patients from the pharmacists’ private filing system (6 
patients). In total 12 pharmaceutical care plans and patients notes were inspected 
retrospectively.  
 
In total 47 patients’ pharmaceutical care plans were reviewed. This comprised 33 






4.1 Literature review 
 
A literature review was performed to try and identify models of pharmaceutical care 
used for patients with diabetes including local service provision in primary and 
secondary care.  
 
The search was performed using MeSH terms in PubMed. In addition searches in 
Embase and freetext searches in PubMed were done. A search in Google was also 
done using similar terms as in PubMed. Examples of terms used are: pharmaceutical 
care model, pharmaceutical care model AND diabetes, pharmaceutical care model 
AND cardiovascular disease, pharmaceutical care, pharmaceutical care AND 
diabetes, pharmaceutical care AND cardiovascular disease, diabetes AND 
cardiovascular disease.  
 
With the help of co-supervisor, pharmacist at clinic A, and co-ordinator of the other 
clinics, other pharmacists who run similar clinics as the study sites were contacted by 
e-mail, to obtain other pharmaceutical care plans to be reviewed.  
 
Furthermore, a review of previous local projects undertaken in this field was done. 
Information about this was provided by the co-supervisor.  
 
Finally searches in sights like The Pharmaceutical Journal (www.pjonline.com), 
British Medical Journal (www.bmj.com), American Diabetes Association 
(www.diabetes.org) and journals like Diabetes Care and Diabetic Medicine were 
performed. Some articles were also found by review of relevant articles reference list.  
 
4.2 Evaluating the pharmaceutical care delivery 
4.2.1 Ethics approval and patient confidentiality 
The study received management approval from the NHS Lothian Director of 
Pharmacy and the Head of Pharmacy Education, Research and Development. As the 
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study was an audit, research Ethics Committee approval was not required. The 
protocol was also approved by the University of Tromsø in collaboration with the 
University of Strathclyde. Patient confidentiality and anonymity was maintained by 
giving each patient a study ID. All identifiable patient information was recorded in a 
separate coding sheet kept with the pharmaceutical care plans at each clinic. The 
data collection code sheet will be destroyed shortly after submitting this thesis.    
 
4.2.2 Data collection form 
A draft data collection form to be used to collect patient data and pharmaceutical care 
issues was developed by the researcher. The draft data collection form was based on 
the pharmaceutical care plan developed from a previous local project (Jude McEntire 
et al 2006 and Caroline Warnock et al 2006) (appendix 1), and now in use at clinic A 
and B, and a diabetes pharmaceutical care plan developed to be used in community 
settings (Dalal Taweel 2007 44) (appendix 2). The data collection form was e-mailed 
to the rest of the project co-supervisors to get feedback on the data fields included. 
Suggestions on changes to the data collection form were implemented in the form 
prior to the data collection period. 
 
4.2.3 Pharmaceutical care issues  
The researcher sat in at three chosen clinics (A, B and C) and recorded patient data 
and pharmaceutical care issues prospectively for the patients seen by the 
pharmacists during the period from 5th of February until 19th of March 2008. Clinic A 
and B run on a weekly basis on different weekdays and would generate many 
patients over a short time period. Clinic C runs only on a monthly basis, but was 
included since this clinic also comprises ethnic minority patients. A comparison of 
possible differences between the clinics could therefore be described. During a seven 
week data collection period the anticipated number of patients would be 96. 
According to the Head Pharmacist of the DCVR clinics the mean number of care 
issues per care episode is four, which would result in approximately a total of 400 
care issues. A temporarily reduction in patients at clinic B, due to many patients 
being discharged from the clinic right before the data collection period started, 
cancellation of clinic dates and patients not showing up for their appointments 
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resulted in a lower number of prospectively included patients. Retrospectively 
patients were therefore also included in the study. Prospectively included patients 
who had a history of clinic attendance prior to the data collection period were also 
studied retrospectively to identify pharmaceutical care issues addressed by the 
pharmacist for a maximum of four previous consecutive clinic visits. Four consecutive 
clinic visits were set as a cut-off point, since this is the mean number of care 
episodes at the clinics 40. All of the patients in the prospective part of the study were 
seen by the pharmacist at least once. 
 
If possible pharmaceutical care plans and patients notes were reviewed by the 
researcher prior to the clinic day. After each patient consultation, the pharmaceutical 
care issues for each patient were discussed by the clinic pharmacist and the 
researcher to ensure that all of the care issues were recorded correctly. After the 
researcher had identified each patient’s retrospective care issues through inspection 
of pharmaceutical care plans, the care issues were discussed with the individual 
pharmacist. This enabled each pharmacist to verify their own pharmaceutical care 
issues.  
 
For the retrospective included patients, a random sample of pharmaceutical care 
plans of 12 patients were collected by the researcher at clinic A from the pharmacists’ 
private filing cabinet. The only inclusion criterion was that the patients had to have 
attended the clinics for more than three care episodes. Patients included were both 
patients under current care by the pharmacist and patients now discharged from the 
clinic. Pharmaceutical care issues were identified from the pharmaceutical care plan 
and with the aid of patient notes. Any questions needed to interpret the care issue 
due to lack of clarity about the documented pharmaceutical care issues was 
discussed with the pharmacist, and the final interpretation verified by her.  
 
All of the included patients from the three different clinics were pooled together (n = 
47), and identified pharmaceutical care issues from the care plans were put in a 
Microsoft Access database. The pharmaceutical care issues were categorised using 
standardised categories of ‘checks’ and ‘changes’, ‘drug therapy problems’ (DTP) 
and ‘quality assurance (QA) descriptors’. The categorisation of DTP was based on a 
system of Cipolle et al 4 and the categorisation of care issues was undertaken using 
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a guideline (appendix 3) developed  by fellow Norwegian student group whose 
project objective was to review the definitions (Kari Husabø, Marit Bergheim 
Christensen, Maren Rambøl Ruud and Reidun Os Husteli). Both the ‘checks’ and the 
‘changes’ were divided into subcategories and categorised according to the ‘QA 
descriptors’ (see appendix 3). Care issues and the different categories of the 
categorisation system were quantified per care episode. It was not suitable to present 
the data expressed per patient, since most of the recruited patients were still under 
current care by the clinic pharmacists. 
 
Descriptive information was prepared in order to describe the study patient sample. 
This included mean age, weight and BMI, distribution of male and female patients, 
distribution of type of diabetes and mean duration of diabetes since time of diagnosis. 
 
4.2.4 Assessment of pharmaceutical care actions in relation to guideline    
standards at clinic A 
 
Patients’ (n = 33) care issues identified from pharmaceutical care plans from clinic A 
were also categorised according to any guideline standard it was addressing for 
patients with chronic cardiovascular disease. Only clinic A was chosen to execute 
this part of the project due to easy access to patients’ notes at this site. The tool used 
is developed at the University of Strathclyde and has been published by Kamyar et al 
45. The guideline standards used were those included in an extended validated 
medication assessment tool (MATCVD) (see appendix 4) developed to measure 
compliance with guideline recommendations for chronic cardiovascular diseases 
developed by PhD student Tobias Dreischulte. The MATCVD could not be applied as 
an audit tool; that is it could not be used to assess patients’ medication in terms of 
patients’ needs and guideline recommendations. This was because documentation of 
the patients was not comprehensive enough to allow that and it was impractical to 
access and interrogate patients’ notes during visits to enable full audit. Rather the 
MATCVD provided a categorisation system for those care issues and those 




The tool is divided into six different sections. The different sections are: 
miscellaneous (covering criteria relating to primary prevention and common to 
different cardiovascular diseases), hypertension, coronary heart disease (CHD), 
chronic heart failure, atrial fibrillation (AF) and warfarin use. All of the patients were 
regarded as falling in the miscellaneous and hypertension category, independent of 
any recorded diagnosis of hypertension. To fall in one of the other categories the 
patient had to have a recorded diagnosis of CHD, chronic heart failure, AF or been 
prescribed warfarin. Only care issues where the outcome was a change in the drug 
therapy of the patient, that is starting a new drug or increasing the dose of a drug, 
were categorised in terms of the guideline standard addressed. Agreement on how to 
categorise the different pharmaceutical actions was decided by the researcher 
together with academic supervisor and co-supervisors.  
 
Examples on how to categorise: 
- If a dose increase was done, this was viewed as an attempt to meet the target dose 
specified in the guideline.  
 
- If a dose increase was not addressing a target dose, because there is no target 
dose specified in a guideline, e.g. calcium channel blockers, then the care issue was 
not categorised as addressing a standard even though it may be optimising dose to 
improve clinical outcomes. The goal, of optimising dose would be reflected in any 
dose change actioned (Change – dose increase subcategory). 
 
- Any addition of antihypertensive therapy (including spironolactone and furosemide) 
or dose increase was a regarded as trying to meet guideline standard for target blood 
pressure, “Achieved a blood pressure of ≤ 130 systolic AND ≤ 80mmHg diastolic” and 
“Achieved a blood pressure of ≤ 140 systolic AND ≤ 85 mmHg diastolic”. 
 
- Any addition of new medication for hypertension was regarded as meeting guideline 
standard 2, “prescribed antihypertensive therapy”. 
 
- Patient started for the first time on a statin was categorised as trying to meet 
guideline standard 3 and 4 “prescribed a statin”, 5 and 6 “prescribed simvastatin at a 
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dose of at least 40 mg or equivalent dose of alternative statin or a documented 
maximum tolerable statin dose” and 8 “total cholesterol ≤ 4 mmol/l”. 
 
- Any increase in statin dose was categorised as addressing guideline standard 5, 6 
and 8. Standard 5 and 6 are, “prescribed simvastatin at a dose of at least 40 mg or 
equivalent dose of alternative statin or a documented maximum tolerable statin 
dose”, standard 8 is “total cholesterol < 4 mmol/L”. 
 
Some care issues therefore address no guideline standard; some care issues 
address one standard and some more than one standard. The frequency of 
standards being addressed is reported as per care episode and in relation to total 
number of guideline standards addressed in each section. 
 
4.2.5 Development of the database 
To develop a database suitable for recording data from both pharmacist-led diabetes 
cardiovascular risk clinics and from pharmacist-led Diabetes Management clinics, the 
researcher reviewed a pharmaceutical care plan developed in a project by Dalal Al-
Taweel 44. This care plan was developed for diabetes type 2 patients and 
systematically based on SCI-DC (Scottish Clinical Information Diabetes 
Collaboration) data fields. The data fields from this care plan (appendix 2) and the 
care plan under current implementation in the different DCVR clinics (appendix 1) 
were compared. Any data fields in the DCVR clinic pharmaceutical care plan which 
were not included in the type 2 diabetes care plan was regarded as essential and 
included in the final database. By combining the data fields from both of the 
pharmaceutical care plans, the completed database may include most of the 
information that the pharmacist would find useful in their pharmaceutical care of the 
patients. The program used to develop the database was Microsoft Access.  
 
Reports that were wanted from the database were: clinical details about the patients 
– blood pressure at first and final visit, number of patients with blood pressure above 
140/80 mmHg, lipid levels (cholesterol and triglycerides) at first and final visit, body 
weight and BMI, number of smokers, high alcohol consumption patients, number of 
medications patients receive at first and final visit, type of medication patients are on, 
 45 
number of patients on specific therapies e.g. ACE- inhibitors, patients renal function 
(eGFR and urine ACR) at first and last visit and also being able to link this to number 
of patients receiving e.g. ACE-inhibitors, liver function and glycaemic control 
(HbA1c). In addition reports on patients receiving dietary and exercise advise, 
patients referred on to other healthcare professionals (nurses, dieticians) and 
pharmaceutical care issues were wanted.  
 
The database was tested for suitability to generate reports on pharmaceutical care 
activities and achievement of outcomes. Completed data collection forms for a few 
numbers of patients were entered retrospectively into the database and different test 
queries were performed, with assistance from the NHS Lothian ERD (Education 
Research and Development) administrator. Throughout the development of the 
database several minor adjustments were made. Tick-boxes were added in some of 
the forms of the database in order to make it easier to generate the desired reports. 
 
4.3 Focus group 
 
A focus group meeting was held 30th of April 2008 at the Royal Infirmary of 
Edinburgh, in order to receive feedback from the DCVR clinic pharmacists. This date 
was already scheduled for a regular meeting of this group. An invitation (appendix 7) 
to the focus group discussion was sent to the participants (see table 1) a week in 
advance, in addition to the project protocol (appendix 8). The researcher together 
with co-supervisors agreed a series of prompt questions to be discussed by the 





Table 1. Participants invited to the focus group meeting 
Patient Care Setting Initials 
Secondary care JR 
Secondary care RA/AM 
Secondary care CP 
Primary care  LK 
Primary care (GP practice) PW 
Secondary care IB 
Secondary care AM 
 
 
The researcher presented the results from the prospective and retrospective 
collection of pharmaceutical care activity at the three different clinics to the 
participants of the focus group (appendix 10). Then the results and questions about 
the relevance of audit for their practice and documentation of pharmaceutical care 
activity were discussed. Feedback on how relevant the participants thought a 
standardised care plan and a database were to their practice was also sought after. 




5.1 Literature review 
 
Studies and articles about diabetes and cardiovascular disease, pharmaceutical care 
models in diabetes and treatment recommendations in guidelines were found, and 
used in this thesis. Literature on previous local projects were also reviewed and used 
in different parts of this thesis to describe the delivery of pharmaceutical care 
provided to diabetes patients. These sources were also used to describe how the 
need for this project has developed.  
 
Pharmaceutical care plans from other similar pharmacist-led clinics were sought 
after. Unfortunately none of the pharmacists that were contacted responded to the e-
mail request. A reminder e-mail was sent out, but this also gave no response. 
 
5.2 Evaluation of the pharmaceutical care delivery 
 
5.2.1 Data collection form 
The data collection form was designed to easily collect patient demographics, 
medical history, drug history and laboratory results from pharmaceutical care plans 
when sitting in the clinic with the patient (appendix 5). Data fields included in the data 
collection form were those included in the developed data base, which facilitated 
easy input of data.  
 
 5.2.2 Patient sample characteristics  
During the data collection period from 5th of February until March 19th 2008 the 
researcher reviewed pharmaceutical care plans for 47 patients from the three 
different clinics (A, B and C). From clinic A, there were 21 prospective patients and 
12 retrospective patients. At clinic B the number of prospective patients was eight in 
the same period, and six for clinic C. Of the 47 patients, three were new patients, 
three were discharged during the data collection period and six of the retrospective 
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patients were already discharged from clinic A. Basic demographic data of the total 
patient sample can be seen in table 2 
  
 
Table 2. Demographic data of the total patient sample (n = 47) 
 Variable  
 
Number (%) 
Age (years)   
 Mean  65.7 
 SD 12.6 
 Range 36-84 
 Median  (IQR) 69 (56,77) 
Gender   
 Male 21 (44.7) 
 Female 26 (55.3) 
Weight (kg)1   
 Mean 92.8 
 SD 22.4 
 Range 50-158 
 Median (IQR) 93 (77,103) 
BMI ( kg/m2)2   
 Mean  34.7 
 SD  6.3 
 Range  22-51 
 Median (IQR) 34 (30,38) 
Type of diabetes    
 Type 1 7 (14.9) 
 Type 2 40 (85.1) 
   
Time since diagnosis of diabetes (years)3 
 Mean 14.9 
 SD  8.9 
 Range 1-38 
 Median (IQR) 13 (9,19) 
1 Calculations from 44 patients with documented weight 
2 Calculations from 40 patients with documented BMI 
3 Calculations from 42 patients with documented time of diagnosis of diabetes 
 
5.2.3 Categorisation of pharmaceutical care issues 
Of the 47 patients recruited to the study the number of care episodes ranged from 
one to six. This gave a total number of 186 care episodes. From the pharmaceutical 
care plans and the prospective collection of data, 727 care issues were identified. 
This reflected a mean (SD) of 3.91 (1.27) care issues per care episode.  
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The pharmaceutical care issues were categorised as checks or changes, where 
changes were divided into Change in drug therapy process and Change in drug 
therapy. All of the care issues categorised as a ‘change in drug therapy’ were also 
categorised according to type of drug therapy problem. In addition the care issues 
were further categorised into quality assurance descriptors. Appendix 3 gives an 
explanation of the different parts of the categorisation system and the different 
subgroups. Table 3-10 summarises the results of the categorisation of care issues. 
 
 
Table 3. Distribution of types of pharmaceutical care Checks (n = 373) in 47 patients managed over 
186 care episodes 
Type of check Count Checks (%) Per care episode 
- Medication needs inquiry 19 5.1 0.10 
    
- Effectiveness inquiry 196 52.5 1.05 
    
- Safety inquiry  144 38.6 0.77 
    
- Compliance inquiry 14 3.8 0.08 
    
Total  373 100.0 2.00 
SD   1.17 
CI (95 %)   (1.84,2.17) 
Median (IQR)   2.00 (1.00,3.00) 
 
A total of 373 checks were made in order to assess the need for additional 
medication, effectiveness and safety of treatment and patient compliance. None of 
these checks revealed any potential or actual drug therapy problems that needed 
further follow-up at this point or change in drug therapy. Most of the checks (91.5%) 
performed by the pharmacist were concerning the effectiveness of patients 
antihypertensive treatment (50.8%) and the safety of treatment (40.7%). The number 
of ‘checks’ performed by the pharmacists is higher than the total number of ‘changes’ 
(373 checks against a total of 354 changes over the overall 186 care episodes, see 
table 4 and 5). Per care episode there were 2.00 (SD 1.17) ‘checks’ made. This is not 
surprising since the most important objective of pharmaceutical care is to prevent 
potential drug therapy problems and therefore many routine checks have to be 
performed. ‘Compliance inquiries’ are performed on a routine basis, and especially if 
there are, for example, any unexpected blood pressure results or cholesterol 
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measurements. The number of ‘compliance inquiries’ is quite low; only 14 inquiries 
are documented over 186 care episodes.  
 
 
Table 4. Distribution of types of Change in drug therapy process (n = 211) in 47 managed over 186 
care episodes 
Changes made to Count Changes (%) Per care episode 
- Clinical (shared) record of patient 
characteristics 
4 1.9  0.02 
    
- Clinical (shared) record of drug 
history 
0 0.0 0.00 
    
- Continuity of information/care 
between clinical settings 
192 91.0 1.03 
    
- Level of patient monitoring  15 7.1 0.08 
    





    
Total  211 100.0 1.13 
SD   0.36 
CI (95 %)   (1.08,1.19) 
Median (IQR)   1.00 (1.00,1.00) 
 
 
Table 4 shows that the total number of changes in drug therapy process was 211. As 
many as 192 (91%) were due to ‘continuity of care/information between clinical 
settings’. This is not surprising in an out-patient clinic where recommendations for 
prescribing are provided to the GP. In addition 15 (7.1%) care issues identified the 
need for increased ‘level of patient monitoring’. Over 186 care episodes the clinical 
shared records of patients’ characteristics were changed four times. This accounts 
for 1.9% of the changes made in drug therapy process.  
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Table 5. Distribution of type of Change in drug therapy (n = 143) in 47 patients managed over 186 
care episodes 
Changes made to Count Changes (%) Per care episode 
- Drug selection (starting new or 
changing drug) 
35 24.5 0.19 
    
- Dose 55 38.4 0.30 
    
- Route/dose form 0 0.0 0.00 
    
- Dose interval/timing 2 1.4 0.01 
    
- Duration 0 0.0 0.00 
    
- Stop drug temporarily/permanently 7 4.9 0.04 
    




    
Total number of change in drug 
therapy 
143 100.0 0.78 
SD   0.84. 
CI (95 %)   (0.65,0.89) 
Median (IQR)   1.00 (0.00,1.00) 
 
 
Looking at table 5, changes to the patient’s drug therapy were performed 143 times 
with a mean (SD) of 0.78 (0.84) per care episode. Most of these changes were dose 
adjustments, which were performed 55 times (38.4%). This is not surprising since the 
nature of the clinic is to provide close follow-up of the patients to achieve control of 
blood pressure by titrating drug doses. A new drug or a change in drug was done 35 
times (24.5%). Again not surprising for those patients whose blood pressure is 
resistant to optimal doses of initial therapy. Of the total number of changes in drug 
therapy, 44 were related to ‘patient or carer understanding/compliance’. This example 
illustrates the lack of documentation of educational activity. It would be expected that 
patients would be provided educational advice on every care episode. There are no 
changes made to the duration of treatment, this is because all of these changes were 




Table 6. Distribution of Drug therapy problems (n = 143) in 47 patients managed over 186 care 
episodes 
Type of drug therapy problem 
(DTP) 
Count DTPs (%) Per care episode 
- Unnecessary drug therapy 1 0.7 ∼ 0.00 
    
- Need for additional drug therapy 31 21.7 0.16 
    
- Ineffective drug 2 1.4 0.01 
    
- Dosage too low 45 31.5 0.24 
    
- Adverse drug reaction 6 4.2 0.03 
    
- Dosage too high 10 7.0 0.05 
    
- Inappropriate compliance 48 33.5 0.26 
    
- Unclassified non-DTP 0 0.0 0.00 
    
Total  143 100.0 0.75 
SD   0.84 
CI (95 %)   (0.65,´0.89) 
Median (IQR)   1.00 (0.00, 1.00) 
 
All care issues categorised as change in drug therapy were also categorised as a 
drug therapy problem, which explains the total number of DTP of 143. Table 6 shows 
that every care issue categorised as a change in dose (n = 55) in table 5, was either 
due to too high dose (n = 10) or too low dose (n = 45). The distribution of DTP also 
illustrates that discontinuation of a drug, either permanently or temporarily (n = 7), 
was due to ‘unnecessary drug therapy’ (n = 1) and ‘adverse drug reactions’ (n = 6). 
All of the pharmacists’ efforts to increase compliance are categorised as 
‘inappropriate compliance’ (48, 33.5%) and includes all of the care issues categorised 
as ‘patient or carer understanding/compliance’ in change in drug therapy process. 
The pharmacists document a mean (SD) of 0.75 (0.84) DTP`s per care episode. 
 
Each pharmaceutical care issues were also categorised according to quality 
assurance descriptors. This part of the categorisation system illustrates that 
pharmaceutical care delivery is a cyclical process. The pharmacist’s role is to 
contribute to improve the quality of this process. The quality assurance descriptors 
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are therefore a tool which helps to identify when in the pharmaceutical care process 
the checks are made and the extent of the changes made to the drug therapy. 
 
 
Table 7. Distribution of total number of pharmaceutical Checks (n = 727) in the quality system 
feedback loop in 47 patients managed over 186 care episodes 
Type of check according to the 
quality system feedback loop 
Count Checks (%) Per care episode 
- Verification 64 8.8 0.34 
    
- Monitoring 646 88.9 3.47 
    
- Confirmation 17 2.3 0.09 
    
Total 727 100.0 3.90 
SD   1.27 
CI (95 %)   (3.73, 4.09) 
Median (IQR)   4.00 (3.00, 5.00) 
 
 
From table 7 one can see that, of the total 727 care issues, 64 (8.8%) ‘verifications’ 
were performed by the pharmacists at the start of a patient treatment/ when the 
pharmacists first assessed the patient. Almost all of the checks made were 
‘monitoring’ checks, 646 (88.9%), made during the patient treatment. Evaluations of 
the patient treatment, ‘confirmations’, were only done 17 times (2.3%), which is not 
surprising in an out-patient setting. 
 
 
Table 8. Distribution of true pharmaceutical Checks (n = 584) in the quality system feedback loop in 47 
patients managed over 186 care episodes 
Time perspective according to the 
quality system feedback loop 
Count Checks (%) Per care episode 
- Verification 48 8.2 0.26 
    
- Monitoring 519 88.9 2.79 
    
- Confirmation 17 2.9 0.09 
    
Total  584 100.0 3.14 
SD   1.21 
CI (95 %)   (2.97, 3.31) 
Median (IQR)   3.00 (2.00, 4.00) 
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Table 8 shows the breakdown to true checks, i.e. time of checks that did not lead to a 
change in the patient’s drug treatment. Most of these checks were ‘monitoring’ 
checks performed to ensure effectiveness and safety of patients’ treatment. In total 
the pharmacists perform 3.14 checks per care episode. 
  
Table 9. Distribution of Changes in drug therapy (n = 143) in the quality system feedbackloop in 47 
patients managed over 186 care episodes 
Degree of change according to the 
quality system feedback loop 
Count Change (%) Per care episode 
- Adjustment 143 100.0 0.77 
    
- Modification 0 0.0 0.00 
    
- Prompt a review 0 0.0 0.00 
    
Total number of degree of change 143 100 0.77 
SD   0.84 
CI (95 %)   (0.65, 0.89) 
Median (IQR)   1.00 (0.00, 1.00) 
 
All of the changes made to the patient’s treatment were categorised as an 
‘adjustment’, 143 (100%). This number reflects that every change made to a patient’s 
treatment was made according to the agreed treatment plan. None of the changes in 
drug therapy identified the need for a change in a patient treatment plan 
(‘modification’) or a need for re-assessment of a patient treatment.  
 
 
Table 10. Distribution of Degree of changes (n = 147) in the quality system feedbackloop, linked to the 
preceding Timer perspective in 47 patients managed over 186 care episodes 
Type of check Type of 
associated change 
Count Check (%) Per care 
episode 
- Verification Adjustment 16 11.2 0.09 
 Modification 0 0.0 0.00 
     
- Monitoring Adjustment 127 88.8 0.68 
     
- Confirmation Modification 0 0.0 0.00 
 Prompt a review 0 0.0 0.00 
Total 143 100 0.77 
SD    0.77 
CI (95 %)    (0.65, 0.89) 
Median (IQR)    1.00 (0.00, 1.00) 
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‘Adjustments’ to patients’ treatment were done 16 times (11.2%) as a result of a 
‘verification’ check done by the pharmacist when they first saw the patient. All of the 
other ‘adjustments’ were performed during the patients’ attendance to the clinic, and 
were the result of ‘monitoring’ checks, 127 (88.8%). 
 
5.2.4 Differences between the three clinics 
No statistical comparison of the different clinics and the pharmacists was done in this 
study. All of the clinics focus on the same main areas; blood pressure lowering, 
control of lipid levels, compliance, and education on disease management and drug 
therapy. The researcher did however when sitting in at the clinic see that the 
pharmacists had different ways of approaching the patients. Mostly these differences 
are directly linked to how the clinic is run. Although there are differences between 
how the clinics are run and types of patient, this may not have any impact on types of 
care issues that are identified by the pharmacists. The following sections are 
therefore the researcher’s own interpretation of the differences between the clinics. 
  
Clinic A is run on a weekly basis and the pharmacist is also there the following day. 
Laboratory results can therefore be checked the day after the clinic, so that the 
patient will be notified quickly if any changes to the treatment have to be done, or if 
any new arrangements have to be made. Dictating or writing letters to the GP`s and 
updating SCI-DC does not necessarily have to be done during the clinic, but could be 
done the next day. On a busy clinic day, this releases extra time to be used on 
patient consultation, writing in the pharmaceutical care plans and discussion of the 
outcome of the clinic with the diabetes consultant. Preparation for next week’s clinic 
is done the second day by review of the care plans and patients’ notes. 
 
Clinic B is also run on a weekly basis, but the pharmacist is just there one day of the 
week. Any results from laboratory tests are therefore checked the following week. 
Changes to patients’ medication is usually made one week after the clinic visit, 
because the results have to be verified before any changes can be made. Writing 
letters to the GP`s and updating SCI-DC are done on the clinic day after discussion 
of the outcomes from the clinic with the diabetes consultant.  Preparations for next 
week’s clinic have to be done in the morning of the clinic day. The pharmacist at this 
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clinic does not always have access to the patient notes, so she has to rely more on 
her own notes in the care plans. As a result of this the pharmacist writes more 
complete notes in her care plans, and this made it easier for the researcher to identify 
PCI`s.  
 
Looking at clinic C, this is a monthly clinic, which also includes ethnic minority 
patients. Many of the patients attending the clinic do not have English as their first 
language. A huge part of the pharmacist’s job is therefore to provide education on 
diabetes management, cardiovascular risks, drug therapy and other educational 
advice in the patient’s own language. This is information that is important for the 
patient to have knowledge about, but that can be difficult for other healthcare 
personnel to provide to this patient group because of the language barrier. A few of 
the patients referred to the clinic do not necessarily have increased cardiovascular 
risk, but are attending the clinic to prevent that. In contrast to the other clinics, the 
pharmacist at clinic C also focuses more on HbA1c and dietary advice. Just like clinic 
B, dictation of GP letters are done on the clinic day and preparation for next clinic is 
done in the morning before the clinic. 
 
5.2.5 Pharmaceutical care actions in relation to guideline standards at 
clinic A 
 
From clinic A, 33 patients and their pharmaceutical care plans were reviewed, which 
gave a total of 129 care episodes. The researcher wanted to find out how many of 
the pharmacist’s actions which resulted in a change in a patients medication was an 
attempt to implement or enforce guideline standards. An overview of the distribution 




Table 11. Distribution of cardiovascular diseases and hypertension in the patient sample from clinic A 
(n = 65 diseases in 33 patients) 





patients (%) n = 33 
Hypertension1 33 (50.8) 33 (100.0) 
Ischaemic heart disease (IHD)2 8 (12.3) 8 (24.2) 
 - Angina  6 (9.2) 6 (18.2) 
 - Myocardial infarction (MI) 2 (3.1) 2 (6.1) 
Coronary artery bypass graft (CABG) 4 (6.2) 4 (12.1) 
Peripheral vascular disease (PVD) 5 (7.7) 5 (15.2) 
Stroke/TIA3 3 (4.6) 3 (9.1) 
 - cerebrovascular disease 3 (4.6) 3 (9.1) 
Atrial fibrillation 1 (1.5) 1 (3.0) 
Total 65 (100.0)  
1 All of the patients were regarded as having hypertension independent of having a recorded diagnosis of such in patient notes 
2 In the patients notes both diagnosis of IHD, angina and MI were used, so no clear indication of what type of IHD the patients 
in the IHD group have 
3 Both Stroke/TIA and cerebrovascular disease were used in patients’ notes 
 
None of the patients in the patient sample were on warfarin and none of the patients 
had a diagnosis of chronic heart failure. These two sections of the MAT tool criteria 
were therefore not included in the survey of criteria addressed by the pharmacists’ 
actions.  
 
Care issues with an outcome of a change in medication to the patient were 
categorised according to if they addressed any guideline standard. There were 51 
care issues leading to a change in drug therapy, which resulted in a total of 130 
guideline standards tried to be met. The frequency of standards tried to be met and 
frequency per care episode are shown in table 12. The table shows only the 




Table 12. Distribution of identified pharmacist care issues (medication changes) in 33 patients in 129 
care episodes at clinic A addressing clinical guideline standards 
# 







1 Invited to join smoking cessation program 0 (0.0) 0.000 
2 Prescribed antihypertensive therapy 16 (51.7) 0.124 
3 Prescribed a statin 1 (3.2) 0.008 
4 Prescribed a statin 1 (3.2) 0.008 
5 Prescribed simvastatin 40 mg or equivalent dose of alternative 
statin or maximum documented tolerated dose 
4 (12.9) 0.031 
6 Prescribed simvastatin 40 mg or equivalent dose of alternative 
statin or maximum documented tolerated dose 
4 (12.9) 0.031 
7 Prescribed an acceptable statin (…) 0 (0.0) 0.000 
8 TC ≤ 4 mmol/l 4 (12.9) 0.031 
9 Prescribed aspirin 75 mg 0 (0.0) 0.000 
10  Prescribed aspirin 75 mg 0 (0.0) 0.000 
11 Prescribed aspirin 75 mg 0 (0.0) 0.000 
12 Achieved a blood pressure ≤ 150/90 mmHg 0 (0.0) 0.000 
13 Prescribed a combination of aspirin plus dipyridamole 0 (0.0) 0.000 
14 Prescribed clopidogrel at a dose of 75 mg instead of aspirin 0 (0.0) 0.000 
15 Prescribed an ACE-inhibitor 1 (3.2) 0.008 
16 Prescribed metformin 0 (0.0) 0.000 
Subtotal  31 (100.0) (0.241) 
Mean (SD)  0.015 (0.031) 
CI (95 %)  * 
Median (IQR)  0.000 (0.000, 0.014) 
Hypertension 
17 Achieved a BP of ≤ 130 mmHg systolic AND  ≤ 80 mmHg diastolic 45 (47.3) 0.349 
18 Achieved a BP of ≤ 140 mmHg systolic AND  ≤ 85 mmHg diastolic 45 (47.3) 0.349 
19 Prescribed a calcium channel blocker or ACE-inhibitor 0 (0.0) 0.000 
20 Prescribed an ACE inhibitor 1 (1.1) 0.008 
21 Prescribed an AII antagonist 0 (0.0) 0.000 
22 Prescribed a thiazide diuretic or calcium channel blocker 4 (4.3) 0.031 
23 NOT prescribed a combination of a thiazide diuretic and a BB 0 (0.0) 0.000 
24 Drugs on specified list are avoided 0 (0.0) 0.000 
Subtotal 95 (100.0)  (0.737) 
Mean (SD)  0.092 (0.159) 
CI (95 %)  * 
Median (IQR)  0.004 (0.000, 0.111) 
CHD 
25 Prescribed a beta-blocker 0 (0.0) 0.000 
26 Prescribed a rate-limiting calcium channel blocker, long acting 
nitrates or nicorandil 
0 (0.0) 0.000 
27 Prescribed a long acting nitrate or nicorandil 0 (0.0) 0.000 
28 Prescribed sublingual glyceryl trinitrate or glyceryl trinitrate spray 0 (0.0) 0.000 
29 Prescribed a calcium channel blocker 0 (0.0) 0.000 
30 Prescribed amlodipine or felodipine 1 (25.0) 0.008 
31 Uses a dosing regimen which avoids the development of tolerance 0 0.000 
32 Prescribed target dose (C 50 mg bd, E 20-40 od, L or R 10 mg od) 
or a documented maximum tolerated dose 
3 (75.0) 0.023 
Subtotal 4 (100.0) 0.031 
Mean (SD)  0.004 (0.008) 
CI (95 %) 
 
* 
Median (IQR)  0.000(0.000, 0.0042 
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Table 12. Continues   
# 






Chronic heart failure 
33 Prescribed target dose (C 50 mg tds, E 10-20 mg bd, L 20 od, R 10 
mg od, P 8 mg od or T 4 mg od) or a documented maximum tolerated 
dose 
x x 
34 Drugs on specified list are avoided x x 
35 Prescribed an AII antagonist x x 
36 Prescribed candesartan x x 
37 Prescribed combination of hydralazine and ISDN  x x 
38 Prescribed target dose (L 50 mg od, C 32 mg od, V 160 mg bd) or a 
documented maximum tolerated dose 
x x 
39 Prescribed a beta blocker (except metoprolol tartrate) x x 
40 Prescribed target dose (C 25-50 mg bd, B or N od) or a documented 
maximum tolerated dose 
x x 
41 Prescribed diuretic treatment x x 
42 Prescribed spironolactone x x 
43 Prescribed eplerenone x x 
44 Prescribed eplerenone x x 
45 Prescribed target dose (S 25-50 mg od, E 50 mg od) or a documented 
maximum tolerated dose 
x x 
46 Prescribed digoxin x x 
47 Receives an annual influenza vaccination x x 
48 Received a once-only pneumococcal vaccination x x 
49 Prescribed a beta blocker or digoxin x x 
AF 
50 Prescribed either a beta-blocker, verapamil, diltiazem or digoxin 0 (0.0) 0.000 
51 Prescribed warfarin 0 (0.0) 0.000 
52 Is prescribed antiplatelet  therapy 0 (0.0) 0.000 
Subtotal 0 (0.0) 0.000 
Mean (SD)  - 
CI (95 %)  - 
Median (IQR)  - 
Warfarin 
53 INR measured in intervals of which none > 12 weeks x x 
54 INR measured within 1 week after dose change or starting each drug x x 
55 INR measured within 1 week after dose change or starting each drug x x 
56 INR history with at least 60 % of INRs witin target range x x 
* Unable to calculate confidence interval because the proportion is too small or too large 
 
 
The reason that the number of guideline standards is higher than the number of care 
issues is that each pharmacist action has the possibility to try and meet several 
guideline standards.  
 
Most of the pharmacist actions resulted in dose adjustments and can therefore be 
viewed as an attempt to met guideline standard 17 and 18. Any new addition of 
antihypertensive therapy is also an attempt to meet the same two standards. The 
number of times standard 17 and 18 was tried to be met was 45 (in 34.9% of the total 
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number of care episodes), which gives a total of 90 standards that were tried to be 
met.  All of the patients have a degree of hypertension, which explains why as many 
as 95 of the guideline standards tried to be met fall into the hypertension section, with 
a mean (SD) of 0.092 (0.159) per care episode. 
 
When looking at the atrial fibrillation section, no guideline standards were addressed 
by the pharmacists identified pharmaceutical care issues in this section. This was 
because only one of the 33 patients had a diagnosis of atrial fibrillation, and this 
patient was only on an antiplatelet agent. Issues regarding warfarin and INR 
(international normalized ratio) measurements are addressed in separate warfarin 
management clinics. Necessary scrutiny does however have to be made in decisions 
regarding changes in medication or drug doses, since warfarin interacts with many 
different medicines. Results from recent INR measurements can be verified if 
necessary from Apex, but these actions would not be regarded as a monitoring check 
and therefore not reflected in these results. 
 
5.3 Pharmaceutical care delivery assessment tool 
 
The care plan in use at clinic A and B (appendix 1) was compared to the diabetes 
pharmaceutical care plan to be used in community settings (appendix 2). The 
diabetes care plan covered most of the data that were recorded at the clinic, but a 
few data fields had to be added from the DCVR pharmaceutical care plan. These 
were: Date of first visit, referral BP, target BP, BP on final visit, target weight, referred 
to dietician and medication checked and verified by. The database is divided into 
different forms; these are outlined in bold in table 13 below. The data fields included 
in each form are also outlined in the table. 
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Table 13. Data fields included in the completed database 
Included data fields 
Patient details 
 - Study ID 
 - Clinic ID 
 - Date of birth 
 - Gender 
 - Age 
 - Height 
 - Weight 
 - Target weight 
 - BMI 
 - Date of first visit 
 - Number of clinic visits 
  
 - Blood pressure measurements 
• Referral blood pressure, target blood pressure, final blood pressure 
  
 - Family history 
• Cardiovascular disease, diabetes, other – specify, unknown  
  
 - Ethnic origin 
• White, black, asian, chinese, other - specify 
  
 - Social history 
• Living alone, living with partner/family, pregnant, breastfeeding, other 
- specify 
  
 - Special needs  
• Sight, hearing, speech, physical, none, other – specify 
  
 - Smoking habit 
• Never smoked, ex-smoker > 5 years, ex-smoker ≤ 5 years, current 
smoker < 10 cpd, current smoker ≥ 10 cpd, unknown 
• Smoking advice given 
  
 - Alcohol consumption 
• No alcohol, within limit, excess limit, unknown 
• Alcohol advice given 
  
 - History of complications 
• Neuropathy, retinopathy, nephropathy, amputations, foot ulcers, 
erectile dysfunction, mood disorder, recurrent infection, 
microalbuminuria1 




Table 13. Continues 
  
 - Medication checked and verified by 
• SCI-DC, GP letter, GP practice, patient, patients own drugs, repeat 
prescription 
  
 Educational needs assessment 
  
 - General advice 
• Diabetes, diabetes control, cardiovascular, complications, diet, 
exercise, smoking cessation 
  
 - Self medication 
• Oral agent timing, missed doses, insulin administration, injection sites, 
written information on medicines 
  
 - Self management 
• Glucose monitoring, monitoring diary, hypos, foot care, intercurrent 
illness, compliance aid, compliance – good, poor or unknown 
  
 - Self management assessment 
• Concordance, comprehension, dexterity 
 - Comments 
 - Referred to dietician 
  
 Relevant medical history 
  
- Year of diagnosis 
 - Diagnosis 
 - Cardiovascular history and diabetes history tic-boxes2  
  
 Drug history 
  
 - Start date 
 - Stop date 
 - Drug (tic-box for cardiovascular medicines, diabetes medicines, other 
relevant medicines including OTC, first clinic visit, last clinic visit, vaccine)2 
 - Dose, route, frequency 
 - Status: annual, current, history 
 - Indication 
 - Allergic reaction 
 - Comments 
  
 Laboratory investigations 
 - Date 
 - Laboratory investigation/marker 
 - Result (tic box for first clinic visit, last clinic visit, out of range)2 
 - Category: Biochemical, LFT`s, lipids, general 
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Table 13. Continues 
 Annual review GP/hospital 
  
 - Date attended 
- Screen: Eye, foot, renal 
- Comment 
- Date due 
  
 Pharmaceutical care activity 
  
- Care issue 
 - Action 
 - Output 
  
 Categorisation of pharmaceutical care issues3 
  
- Check: Medication need, effectiveness, safety, compliance 
  
 - Change in drug therapy process: Record of patient characteristics, record 
of drug history, continuity of care information/care between clinical settings, 
level of patient monitoring, health care team member(s) 
education/information  
  
 - Change in drug therapy: Drug selection, dose, route/dose form, dose 
interval/ timing, duration, stop drug temporarily/permanently, patient or carer 
understanding/ compliance 
  
 - DTP code: Unnecessary drug therapy, need for additional drug therapy, 
ineffective drug, dosage too low, adverse drug reaction, dosage too high, 
inappropriate compliance, unclassified non-DTP  
  
 - Quality assurance – Time perspective: Verification, monitoring, 
confirmation 
  
 - Quality assurance – degree of change: Adjustment, modification, review  
  
1 Added after field testing of data collection form 
2 Added to be able to do relevant queries 




5.4 Focus group 
 
The focus group meeting was held on the 30th of April at Royal Infirmary of 
Edinburgh. Not all the pharmacists from the different DCVR clinics were able to 
attend the meeting. This was not necessary to get a useful discussion of the topics of 
the focus group. However all of the pharmacists involved in the data collection were 
present. All of the pharmacists present can be viewed in table 14.  
 
In addition the academic co-supervisor was present to take notes and helped guide 
the discussion together with the researcher. To allow external validation, the whole 
discussion was tape recorded and subsequently transcribed (appendix 6). The 
transcript does not include the researcher’s presentation of the results, only the 
questions asked to initiate the discussion.  
  
  
Table 14. Participants (pharmacists) present at the focus group 
Type of Patient Care Setting Initials 
Secondary care JR 
Secondary care RA 
Secondary care CP 
Primary care LK 
Secondary care AC 
 
 
Results as a reflection of practice 
The findings from the focus group revealed that the pharmacists thought that the 
results did reflect what they did in practice. However questions were raised in regards 
of how they record pharmaceutical actions. Not all of their actions are written in the 
care plans and that was taken up as a reason for some of the discrepancy from the 
results. Instead of writing it on the care plans, many of the actions performed by the 
pharmacist are written directly into SCI-DC, or in some cases not written down at all. 
 
“ … I know I change the drug from SCI-DC, but I don’t always say that in my notes 
care plan, cause you do it, and you say increase dose and then you go and make it 
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in SCI-DC, but you then don’t go back and say: changed it in SCI-DC, because you 
already said dose changed.” (Pharmacist 1) 
 
“(…) the thing with me is I don’t write down enough of what I say. Because I mean I’m 
not- I’m doing it, but it’s not clear enough that I’m doing it… (…).” (Pharmacist 2) 
 
“And also if seeing patients notes, sometimes you don’t write everything in your own 
notes, but when your dictating the letter. You know it’s gonna be in the letter, so if 
(…).” (Pharmacist 1) 
 
 
The relevance of this kind of audit to their practice 
Many of the pharmacists did think auditing their practice was relevant. This was 
mainly because the results made them reflect on how they performed their job and 
also ways to improve the service they are providing. One of the pharmacists thought 
that it was quite interesting that there was such a big difference in the different 
categories; that the high numbers were so much higher than the low numbers. 
 
“(…) whether we are not touching on it or whether it is not necessary or (…).” 
(Pharmacist 2) “… Or if it’s not documented, and that’s the numbers of record of drug 
history.” (Pharmacist 5) “We’re doing that (clinical shared record of patient 
characteristics and clinical shared record of drug history), but we are not 
documenting it.” (Pharmacist 2 and 5) 
 
Another pharmacist felt that the low number of compliance inquiries was an important 
issue. This was also recognised by many of the other participants. Without sufficient 
information about the medicines the patients are taking, pharmacists are unable to 
review their treatment. 
 
“The thing is I’m having more problems with the compliance inquiries illuming, 
because a huge part of the patients don’t know what they’re taking. And unless they 
bring in their medicine…their actually (…) having complications I think, I would have 
to look it over (…). I’m going to ask them to bring them in (…). That should be quite 
interesting, but the whole interaction is based on the quality of everything of what 
they’re taking, and why (…) taking.” (Pharmacist 3)  
 
“I only always do a (medication review) if they bring their tablets, because like you 
(Pharmacist 3), I just don’t trust them.” (Pharmacist 1) 
 
“Next time, bring your tablets. All my tablets? Yes, all your tablets. And we’ll go 
through… and then I get them to say, what’s that for, what’s that for? How do you 
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take it? And that’s how I find out what their taking and if they know what it’s for. And if 
they say: Oh, my daughter fills it. And I say: Well, can your daughter come in next 
time?” (Pharmacist 1)  
 
“So I think that is something that we could probably build on and improve the 
problem.” (Pharmacist 3) 
 
It also came up in the discussion how one could continue to do audits in the future. 
As one pharmacist pointed out, it has to be easy to execute and feasible to do in the 
time available at the clinics. 
 
“(…) so it’s got to be useful and functional, but it’s got to be slick. And then there is 
the other side of; should we do it all the time or should we do it periodically. You 
know again, if you do it all the time and people get tired and they are not good at 
filling in and all that. But if you actually want a good data collection do it for a (…) 
period (…).” (Pharmacist 3) 
 
“(…)You were having to make assumptions based on what you could see and what 
you thought was going on…Ehm…so that might be a bit of a problem with it. The 
other way of doing it would be for us to, as we go along; categorise, but then again 
there is interperson variation of what we think…” (Pharmacist 3) 
 
 
This kind of audit would help in the argument for pharmacist-led clinics 
rather than nurse-led clinics 
 
Participants found it at first difficult to discuss the benefits about pharmacist-led 
clinics over nurse-led clinics. One of the pharmacists said that pharmacists are not 
promoting their success and that they therefore let themselves down. It was 
suggested that the comparison should be with doctors instead of nurses and 
importantly, as one pharmacist pointed out - does a comparison have to be made? 
 
“But I think what we said about comparing it to nurses, you know, to promote the role 
of pharmacist-led clinics we need to say pharmacist do X, Y and Z and nurses 
actually do X. And you would get more value for money. But there would have to be a 
comparison which you could use to say, well this is the parameters we have 
measured and in a previous nurse study, this is what we measured, therefore…you 
are getting more value for money…” (Pharmacist 1) 
 
“It is interesting, when the doctors see their patients in GP practices (…) and check 
their HbA1c, you know, and they’ve got ten, 15 minutes. A medication discussion 
can’t be done in that time; we need a lot longer.” (Pharmacist 5) 
 
 67 
“(…) I think it is unfair for me to have to compare, we’re constantly having to justify 
our position, but nurses don't have to justify their position, doctors don’t have to 
justify their position (…).” (Pharmacist 3) 
 
 
The value of documenting their contribution to pharmaceutical care 
All of the pharmacists recognised the need to document their contribution to 
pharmaceutical care, but there was difference in opinion on what to document and to 
what extent. For example, not everything is written down in the pharmaceutical care 
plans, since they also document care on SCI-DC and write letters to the patients 
GP`s. 
 
“If you don’t document it, then it’s pointless so, then…” (Pharmacist 3) 
 
“Why don’t we just write into patients notes?” (Pharmacist 1) 
 
“I think if you are aware of the need to document, then you’re probably in most cases 
to do so within your time constraint in the clinic. And I think X`s project has 
demonstrated quite (…) now, that there is a need to document effort over clinical 
outcomes…”.  (Pharmacist 4) 
 
“Maybe there is a way of looking at the key, common care issues, coding them and 
having them on each care plan, so that you are just ticking it  (…) so that it is not very 
labour intensive (…).” (Pharmacist 4) 
 
 
Audit as a method to provide consistent practice 
One pharmacist stated that the practice was consistent within the different clinics, but 
that this was probably not easily recognised. 
 
“(…) the care is quite consistent, but we are maybe not, because we are not 
recording it, we maybe can’t see as much of the consistency that is actually 
happening (…).” (Pharmacist 3)  
 
 
Database as an assessment tool 
Most of the pharmacists were positive about the database and felt that it contained 
most of the information/ data fields they would want to have in a tool like this. A 
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couple of limitations were raised regarding the usefulness of the database. The first 
was the absence of connection to SCI-DC and the second was that a database is 
much more labour intensive than the Microsoft Excel spreadsheet that the 
pharmacists now use. The potential of the database to produce reports for use by the 
DCVR pharmacists, but also for higher management were suggested.   
 
“And who else could have access to it? If you go to SCI-DC, you know who the last 
person was that was following that patient. Another clinician checks to see, oh I 
wonder what the pharmacist did? So you know, you still have to go to SCI-DC to do 
patients visits, so that it is recorded, but that you actually saw them (…).”  
(Pharmacist 1) 
 
“(…) other healthcare professionals need to have access to what we are doing, 
because if they are currently unaware of what we are doing, then they need to be 
able to see what we are doing. And if they don’t have access to our paper notes (…).” 
(Pharmacist 1) 
 
A few of the pharmacists said that a database is labour intense, but pointed out that 
most of the workload would be only at the first clinic visit. It would therefore be 
possible to use it as an up to date database where audit data could be derived 
periodically. This would enable continuous audit of practice.  
 
“(…) we talk about just using this as a first visit and final visit. It would be interesting 
to use it as an up to date database, it surely is (…).” (Pharmacist 3) 
 
Prompted a change in practice 
Many of the pharmacists gave the expression that this had prompted reconsideration 
of their views, both on how they document their activity and the need to continue 
auditing their practice.  
 
“I think we need to look at (…) what we are doing and how we are auditing and how 
we would want to be auditing.” (Pharmacist 4) 
 
“I’ll certainly contact X about what indicators (…) something like safety, that’s an 
obvious one. And that we could easily construct from our figures now – patient safety 
(…) you know yourself there are so many incidents on a daily basis, where patients 
doses have to be reduced or adverse effects or you know (…).”   (Pharmacist 4) 
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6 Discussion 
6.1 Principal findings 
 
Evaluation of the pharmaceutical care delivery to diabetes patients with high 
cardiovascular risk in this study, focused on pharmaceutical care issues addressing 
optimisation of pharmacotherapy, patient education and implementation of evidence-
based guideline standards for reduction in cardiovascular risk factors. 
 
As previously described, this study highlighted the lack of pharmacist documentation 
of pharmaceutical care issues and pharmacist actions in the pharmaceutical care 
plans. Only 14 compliance inquiries and 44 episodes of patient education were 
documented over the 186 care episodes. In addition, only four pharmaceutical care 
issues addressing updating the clinical shared records were identified. However, the 
number of effectiveness and safety inquiries was high. Starting patients on new drugs 
and dose adjustments were also high, suggesting that only the most important 
pharmaceutical care issues involving changes to the patients’ treatment are 
documented in the pharmaceutical care plans. However, diabetes is associated with 
many serious long-term conditions which may have a huge impact on patients’ quality 
of life. By providing structured patient education the patients will get equipped with 
the knowledge, skills and confidence to tackle their condition and ultimately prevent 
diabetes related complications.  
 
Currently, within Scotland, the Government have trough “The Diabetes Framework 
Action Plan” pinned down patient education as a key issue in the management of 
diabetes patients 8. This is best achieved through consistent standard information 
provided by healthcare professionals. Patients in this study had regular visits to the 
DCVR clinics (at least every 6 to 8) weeks to follow-up their treatment, and this 
should provide the opportunity for continuous reinforcement of information. Education 
on their condition, the need for treatment and how their medicines work may help 
improve compliance. Compliance is checked by the pharmacists through self-
reporting and repeat prescriptions. As it was discussed at the focus group meeting, 
this is not a reliable method for measuring compliance. A better solution would be to 
ask the patients to bring with them all of their medications at the first clinic visit and 
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then do a full medication review. Assessment of compliance may then be carried out 
early in the care process and this could have a positive effect on compliance and 
consequently on clinical outcomes. Patients with diabetes and high cardiovascular 
risk, like this study population, frequently have very complicated drug regimens. This 
can result in adverse effects and potential compliance issues. Continuous 
assessment and surveillance is therefore important in the successful management of 
chronic diseases, illustrated by diabetes and related hypertension. Patients are 
provided with information and education during the clinic visits, but it is in many cases 
not written down in the pharmaceutical care plans. The same is true for changes 
made to clinical shared records; the records are updated, but the actions are not 
written down in the pharmaceutical care plan. The discrepancies from practice 
prompt the pharmacist’s need to document identified pharmaceutical care issues and 
pharmacists actions. For pharmacists to demonstrate their worth, the standard of 
pharmacist documentation needs to improve. This study resulted in a database 
suitable for recording patient data and pharmaceutical care issues. A tool like this 
would help in standardising the approach and documentation of the pharmacists. 
Through practical use of the database in the handling of collected data, it has been 
demonstrated that useful reports on the pharmaceutical care delivery can be 
generated. 
 
The study focused on the assessment and monitoring of three main focus areas: 
hypertension, dyslipidaemia and diabetes, but this was not to the exclusion of other 
pharmaceutical care issues related to other conditions identified in the assessment of 
the patients. This resulted in identification of a significant number of PCI`s 
necessitating drug alterations and/or dose adjustments to reach target blood 
pressure and lipid levels. The implementation of changes to the patients’ treatments 
were discussed and agreed with the diabetes consultants before written 
recommendations were sent to the GP`s. Although many of the pharmacists in the 
DCVR clinics are supplementary prescribers, and some are on their way to become 
independent prescribers, changes to a patient’s medication have to be done by 
written recommendations to their GP. Hospitals in Scotland do not provide out-patient 
prescriptions as the cost of the medications is paid for by the Community Health 
Partnerships which all GP surgeries belongs to. The only prescriptions provided are 
for specialist clinics where the medications are only available on the advice of a 
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specialist consultant, and/ or the medication has to be made in the hospital pharmacy 
e.g. oncology and dermatology clinics. The prescribing practice is in this way due to 
accountability, responsibility and economic reasons. All care issues categorised as 
Change in drug therapy (table 6) are therefore indirect changes initiated by the 
pharmacist to the GP`s. The GPs are the ones involved in the direct change, since 
they ultimately write the prescriptions. The implementation of changes to the 
treatment may therefore in many cases be delayed, due to the prolonged pathway 
the patients have to go through to receive their new medications. This may also be 
one contributing factor for poor compliance in some patients.  
 
Periodically audits were recognised by the DCVR pharmacists as an important 
method to ensure consistent practice of delivery of pharmaceutical care. They also 
acknowledge the necessity to focus on not just clinical outcomes, but also their 
contribution to pharmaceutical care of the patients, by identifying pharmaceutical care 
issues. Categorisation of pharmaceutical care issues provides a basis of quantitative 
description of the care provided.  
 
6.2 Strengths and limitations of the study 
6.2.1 Pharmaceutical care delivery 
Pharmaceutical care is difficult to evaluate due to its complexity. Since 
pharmaceutical care is provided through a multidisciplinary approach, it is difficult to 
attribute any change in outcome solely on the pharmacist. By identifying PCI`s and 
pharmacist actions and subsequently systematically categorise these, it is possible to 
quantify pharmacists contribution to pharmaceutical care. In this study, the care 
issues were divided into ‘checks’, ‘changes’, ‘DTP`s’ and ‘quality assurance 
descriptors’. The changes were again divided into ‘Change in drug therapy process’ 
and ‘Change in drug therapy’. This division makes it possible to distinguish between 
changes or activities performed by the pharmacist which do not result in any change 
in the drug therapy for the patient, and changes which do result in a change in the 
patient drug therapy. In clinics such as the DCVR clinics there are a lot of ‘Changes 
in drug therapy process’ which have to be performed every clinic visit. Treatment 
recommendations and letters to the GP`s, any referrals to other healthcare 
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professionals such as dieticians, and updating SCI-DC are all important examples of 
such activities performed by the pharmacist. These are activities that not directly lead 
to any change in the patient treatment, but still constitute a huge part of the 
pharmacists’ contribution to pharmaceutical care. It is therefore important to also 
quantify these actions.  
 
The data collection period was only over seven weeks, which resulted in 35 
prospective patients included. This number of patients is much lower than the 
expected number of patients of 96. However, this is due to natural occurring 
incidences as mentioned earlier (see methods). Number of patients included from 
each of the clinics is also different. This was due to the limited project time frame. 
These circumstances are of importance to what conclusions that could be drawn from 
this project. Had the data collection period could have been prolonged it would have 
been possible to get comparable patient samples from all of the sites. In this study 
retrospective patients were also included and PCI`s were also collected 
retrospectively for the prospective patients included in the study. Consequently, the 
number of patients, 47 patients with a total number of 186 care episodes, would 
therefore be expected to give a reasonable resolution of the PCI`s identified by the 
DCVR clinic pharmacists.  
 
Although PCI`s were collected prospectively, the majority of them were collected 
retrospectively from pharmaceutical care plans. The data from the categorisation are 
therefore regarded as an illustration of the documented pharmaceutical care activity 
of the pharmacists. Some of the PCI`s identified by the pharmacists are not written 
down in the pharmaceutical care plan, but in the letter detailing the outcome of the 
clinic visit to the GP. Since most of the data collection was limited to inspection of 
pharmaceutical care plans, these care issues would not have been picked up. Had 
only prospectively PCI`s been categorised, one would therefore suspect that the 
distribution of PCI`s would be different, due to the lack of documentation. A 
prospective approach would enable the data collection of PCI`s to be based on 
actual PCI`s identified by the pharmacists, and not from their memory and what is 
written down in the pharmaceutical care plan. This would also have shown a 
reflection of the exact standard of pharmaceutical care provided at the clinics within 
the data collection period.  
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Looking at the distribution of true ‘time of check’ as many as 88.9% were categorised 
as ‘monitoring’ checks performed during the patient treatment. As a comparison, only 
8.2% and 2.9% were categorised as ‘verification’ and ‘confirmation’, respectively. 
This large variation in the frequency of each subcategory could be attributable to the 
study design. Most of the patients included were under current care in the clinics, and 
many first clinic visits did not match the inclusion criteria (maximum of four 
retrospective consecutive clinic visits). For the same reason, there were also not 
many patients discharged from the clinic during the data collection period. Most 
‘verifications’ are done in the first care episode and the majority of ‘confirmations’ are 
done in the last care episode. The number of ‘verifications’ and ‘confirmations’ may 
therefore be an underestimate of the actual number of care issues categorised in 
these subgroups of the ‘quality assurance descriptors’. 
 
Over 186 care episodes a total number of 727 pharmaceutical care issues were 
identified and categorised. The only way of assuring the quality of categorisation was 
to strictly follow the guideline (appendix 3) and the examples of categorised 
pharmaceutical care issues developed by fellow Norwegian students. This ensured 
consistency in the categorisation process. Since the guideline has just recently been 
developed, the number of people with familiarity and experience in using this system 
is limited. It was therefore not possible to perform an inter-rater reliability test to 
ensure consistent application of the categorisation system. In future the researcher 
would therefore recommend having a training session for future students before 
starting on projects like this. In the researcher experience difficulties in the 
interpretation of different care issues are often easier to discover when applying the 
system in practice. Then problems in the application of the system can be dealt with 
early in the process, rather than during the use of the categorisation system. Through 
discussion, the different interpretations of the different parts of the categorisation 
system can be resolved. This will provide necessary quality assurance of the final 
results.  
 
Pharmaceutical care issues with unknown outcomes are incomplete and were 
therefore not included in the categorisation system. This was because it is no way of 
knowing if the care issue was followed up by the pharmacist or if it was just not 
documented. By having a prospective research approach to the collection of care 
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issues this allowed most gaps in documentation to be filled by inquiry of the 
pharmacist responsible for the care of the patients in the study. Some outcomes 
could nevertheless not be categorised. This was due to an outcome that was not able 
to be verified by the pharmacist, or that the outcome of the care issue was still under 
investigation. One example of the first scenario is when the pharmacist asks the GP 
to recheck laboratory results and the GP surgery is not linked to the Apex system. 
The outcome of the care issue is then unknown if the patient cannot personally verify 
that the tests have been done. If there is no way of verifying the outcome, the 
pharmacist will in most cases then make sure new laboratory tests are done. The 
latter scenario is due to the close proximity of the termination of the data collection 
and the generation of the results. Some of the pharmaceutical care checks performed 
by the pharmacists take a long time to get the results from, and the outcomes were 
therefore unknown when the PCI`s were categorised. In both of these scenarios the 
care issues could not be included in the categorisation system.  
 
No analysis of number of care issues without outcome was made in this study since 
all care issues without outcome were followed up by the researcher. It is therefore not 
possible to know if the care issue would have been followed up by the pharmacist or 
not if the researcher had not been so actively involved. If solely a retrospective 
approach was used, the number of care issues with no outcome may have been of 
interest. This could have provided information of the percentage of care issues the 
pharmacist has time to follow up.  
 
6.2.2 Pharmaceutical care issues addressing guideline standards 
The guideline standards included in the medication assessment tool is limited. This is 
because the tool is developed to be applied on the targeted population of the 
average practitioner and therefore the average patient. In specialised clinics, like the 
DCVR clinics, there are circumstances when it may be most appropriate to deviate 
from clinical guidelines. Especially in complex cases, such as the patients attending 
the clinic, where many of them have associated multiple comorbidities and are 
resistant to standard therapies. In these cases there is a need to clearly document 
prescribing decisions in the medical records. In an out-patient setting like this, it is 
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also important to justify these decisions to the GP`s, since they are the ones that 
ultimately writes the prescription and follows up the patient after discharge.  
 
The most treatment-resistant patients at the clinic are prescribed spironolactone as a 
last step to try and lower their blood pressure. Spironolactone has no indication for 
use in the treatment of hypertension in the BNF (British National Formulary) and in 
cardiovascular diseases it is mainly used to treat congestive heart failure due to its 
diuretic effect 46. However, in treatment-resistant cases of hypertension the use of 
spironolactone could have an impressive blood pressure lowering effect 47. Loop-
diuretics, e.g. furosemide, are also prescribed to many of the patients attending the 
clinic. This drug-class does not have a place in the treatment of hypertension except 
in patients with impaired renal function and/or heart failure 47. These two drug classes 
were not included in the list of antihypertensive drugs defined in the MAT. For the 
purpose of this study, these drugs were included in the list of antihypertensive drugs. 
This is a good example of how a single MAT tool is not applicable in all patient 
populations.  
 
Many of the standards in the MAT were not addressed by the pharmacist over the 
129 care episodes. This is due to a number of reasons. To not include all care 
episodes for each patient in the study could be criticised for not providing the 
complete picture of the pharmacist’s effort of implementing guideline standards. The 
patients referred to the clinic are also, in the majority of cases, already on 
antihypertensive drugs or have tried a lot of different ones, and many of the treatment 
standards are therefore already implemented. The pharmacist will in such cases 
review the patient’s previous and current drug history to ensure that the treatment 
follows the treatment guidelines. Any changes that are recommended to the 
treatment would therefore follow the patient’s subsequent treatment step. Because of 
the before mentioned reasons, no conclusion can be drawn by the researcher about 
what standards the pharmacist should be addressing, but is currently not addressing. 
It is however possible to see which standards are most frequently enforced.   
 
The MAT could not be applied as an audit tool since it was not time to do a full 
medical record review. Pharmaceutical care issues were instead categorised 
according to which guideline standards were being enforced without any predefined 
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audit standard. The qualifying statement for each standard was also not taken under 
consideration to ensure that the standards were applicable. Instead the researcher 
together with the research group (comprising academic supervisor, clinical supervisor 
and co- academic supervisor) agreed a set of examples on how to categorise the 
care issues according to the standards. This ensured consistency in categorisation 
by the researcher. The results from this part of the project are therefore not based on 
a validated method. This method strictly shows the guideline standards which are 
frequently enforced by the pharmacists actions. In order to conduct a successful audit 
one have to set clear standards, observe current practice and compare practice 
against the preset standards. Findings can then identify problems areas or confirm 
either that current practice is effective or that there is an identified need to implement 
changes.   
 
6.2.3 The database as an assessment tool 
By entering in patient information and laboratory results, it is shown that the database 
can be used as an assessment tool in the achievement of clinical outcomes. Wider 
application of the possible uses of the database could therefore be explored. Another 
advantage is that data entered electronically are more standardised and would 
facilitate a more uniform way of recording patient data and outcomes.  
 
Since the database comprises all data fields included in the current DCVR care plan, 
this could make it applicable as an up to date database. Its practical use would then 
not be restricted to be applied just as a periodically audit tool. As the categorisation 
system is already integrated into the database this could be used in the clinical utility 
of clinical recommendations and for quality improvement and research purposes. 
Currently, the pharmacist’s main focus in the clinic is on cardiovascular risk factors, 
and to a lesser degree on diabetes management. This is because these patients are 
already receiving a multidisciplinary follow-up of their condition since they are a part 
of the out-patient diabetes clinic at the different sites.   
 
In smaller communities and in the future, pharmacists will most likely provide a more 
holistic approach in patients’ management of diabetes. The database already 
comprises most of the necessary data fields to record pharmaceutical care issues 
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related to diabetes since it is based on data fields derived from SCI-DC. It would 
therefore also be applicable for use in pharmacist-led Diabetes Management clinics.   
 
The database has also several limitations. First, the development of this database 
began before it was completely made clear which reports were wanted to be 
produced. The person assisting in the practical development of the database also 
had only limited experience in Microsoft Access. Adjustments were therefore made 
accordingly in each successive phase of the development. The desired reports for 
the purpose of this study were therefore able to be generated from the database. If 
more complex reports are wanted, it may be necessary to do some adjustment to the 
configuration. Careful planning and consideration of the nature of the reports one 
wants to produce is best done before the actual construction of the database begins. 
This will make it easier to create the necessary relationships between the different 
forms in the database. Furthermore, some of the patient data and especially the 
laboratory investigations take a lot of time to key in. Several changes to the database 
may have to be made before its potential could be fully utilised.   
 
6.3 Comparison to other studies 
 
6.3.1 Categorisation of pharmaceutical care issues 
Currently there is not a universal agreed system which is systematically developed 
and tested for reliability and validity in categorisation of pharmaceutical care issues. 
This makes it difficult to compare different studies and patient populations. Most 
studies therefore create their own lists of categories when evaluating the 
pharmacists’ contribution to pharmaceutical care.  
 
One study 14, evaluated the feasibility and impact of a community pharmacist input as 
a member of the multidisciplinary team for 62 patients with type 2 diabetes. 
Pharmaceutical care issues were divided into three categories: (1) drug therapy 
problems (according to the Hepler and Strand classification 2), (2) monitoring and (3) 
patient knowledge. In total 178 PCI`s were identified (mean [range] 2.9 [1-5] per 
patient). This represented 76 drug therapy problems, 21 monitoring checks and 81 
care issues related to patient knowledge. The percentage of monitoring checks were 
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higher in our study, but since the categories and the care issues included in each 
category is different, it is not possible to speculate of any reason for this difference.  
 
Another study 39 investigated the pharmaceutical care delivery at one of the DCVR 
clinics by retrospective review of pharmaceutical care plans for 134 patients. This led 
to the identification of 490 pharmaceutical care issues, 941 changes and 1034 
monitoring checks. Although many of the categories included in that study are the 
same as in this study and the study population is the same, a statistical comparison 
cannot be made. This is due to that the fact that the categories have been slightly 
changed and so not been applied in the same way. The most frequent 
pharmaceutical care issues addressed by the pharmacist in that study were 
optimization of antihypertensive dosage, prescription of additional drug therapy and 
avoidance of adverse drug reactions. These are also the most frequent drug therapy 
problems identified in our study, suggesting that the pharmaceutical care delivery is 
nevertheless quite consistent even though the care issues are categorised somewhat 
differently.    
 
A third study 7, developed and tested a system for documenting pharmaceutical care 
issues in the delivery of chemotherapy to cancer patients. From 171 pharmaceutical 
care plans, 430 recorded pharmaceutical care issues (0.7 per patient episode) were 
entered in the database. These PCI`s represented 238 monitoring checks, largely 
due to safety inquiries, and 192 pharmacist initiated changes to drug therapy. Of the 
documented drug therapy changes 48% addressed drug selection issues, 29% 
inappropriate doses and 15% inappropriate dosing intervals or duration of therapy. 
The categories used in that study, did also include many of the same categories used 
in our study, but as mentioned before, a comparison is hard to do because of 
different application of the categories and the unmatched study population.    
 
6.3.2 Application of Medication Assessment Tools 
A medication assessment tool (MAT) incorporates clinical guideline standards that 
should be met in relation to certain inclusion criteria. Tools like this is used in audits 
to optimise interventions based on evidence-based guidelines and through this 
enforce best clinical practise to improve patient outcomes. In one study 45, a previous 
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developed medication assessment tool for coronary heart disease (MAT-CHD) were 
applied to 208 diabetes type 2 patients, with or without ischemic heart disease, 
attending a primary care medical centre. The study showed that overall adherence to 
guideline criteria was significantly lower in secondary prevention than for primary 
prevention of coronary heart disease (74% vs. 80%, P< 0.05; Chi square). The tool 
highlighted areas for review and possible improvement in clinical guideline 
implementation for the prevention of CHD.  
 
In another study, an evidence based MAT tool was applied in a diabetes out-patients 
clinic to 214 patients to measure the quality of prescribing of drug therapy for 
cardiovascular disease in diabetes patients 48. The three criteria with the lowest 
adherence were “achievement of target blood pressure in patients on 
antihypertensives” (43%), “use of aspirin in primary prevention of CHD” (51%) and 
“use of ACE inhibitors in patients with defined risk factors” (55%). This highlighted the 
need to improve prescribing practice in antihypertensive management in patients with 
diabetes. It also reflected the known difficulties in achieving target blood pressures. 
 
Since the MAT-CVD could not be applied as an audit tool in this study, it is difficult to 
compare any of the findings with the results from the two other studies. However, 
both these studies highlighted areas of the clinical guidelines which offer a means of 
co-operation between supplementary/independent prescribers and the GP. 
Guidelines implemented in this study did also highlight areas in which pharmacists 
play an important part in assuring the quality of care provided to these patients. The 
guideline standards most frequently addressed by the pharmacist in our study, 
“achievement of target blood pressure” and “prescribed antihypertensive therapy”, 
are addressing some of the identified criteria with low adherence in the study situated 
in the diabetes out-patient setting 48. This would suggest that the pharmacist 




6.4 Future considerations 
6.4.1 Implications of the study to practice 
The categorisation of pharmaceutical care issues has provided a good method of 
evaluating the pharmaceutical care delivery at the clinics. Findings from the audit 
suggested lack of documentation of some pharmaceutical care issues and 
pharmacist activities. These were discussed in the focus group meeting comprising 
the DCVR clinic pharmacists. Discrepancies between the results and practice were 
highlighted and reviewed, and periodically audits were endorsed by the pharmacists 
as a method showing their contribution to the pharmaceutical care process. Although, 
the results can not be used to say if the pharmaceutical care delivery is consistent 
within the different clinics, due to limited number of clinics included, they do provide 
necessary evidence on the pharmacists’ contribution to the management of 
cardiovascular risk factors in diabetes patients. However, increased emphasis on 
auditing of practice and standard ways of documentation will ensure consistent 
practice in the future.  
 
As of now, the project has resulted in the development of a database suitable for 
recording patient details, clinical outcomes and pharmaceutical care issues. The aim 
would be to implement the necessary data fields for the pharmacist into the SCI-DC 
database. A shared medical record will make sure that pharmacists can be shown to 
be doing the right thing in individual patient care. Auditing the service and evaluating 
it through research will make sure that pharmacist can be shown to be doing the right 
thing to a group of patients. A clinical shared record would also enable other 
healthcare providers to more clearly see what the pharmacist contribute with, and 
ensure a more efficient communication pathway between pharmacists and GP`s, and 
also other members in the diabetes management multidisciplinary team. 
 
This study has highlighted the need to improve pharmacist documentation. It is 
important that pharmacist document evidence showing positive outcomes in the 
management of diabetes patients. Broadcasting of this information would be 
valuable, because it may raise the awareness of other healthcare professionals 
regarding pharmacists as effective clinicians involved in the management of diabetes 
patients. This increased awareness could elevate pharmacists profile and support 
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their engagement in specialised clinics, as the DCVR clinics are, and also 
pharmacists’ contribution to pharmaceutical care in other parts of the healthcare 
service. Pharmacists have already been endorsed as important healthcare providers 
through the expansion of prescribing rights to independent prescribing and though 
the chronic medication service in the new Scottish community pharmacy program 11.  
 
The database can be used to generate reports of the pharmacists’ activities when it 
comes to both clinical outcomes and pharmaceutical care issues. These reports can 
be provided to higher management to shown the added benefit of having 
pharmacists included in the multidisciplinary team, and possibly help secure 
reimbursement of pharmacist services.  
 
The database can also be used as a tool to generate reports to demonstrate risk 
management activity, assess pharmaceutical care needs and may help to inform 
strategic decisions in the development of pharmaceutical care services. By showing 
positive reports on the pharmaceutical care delivery that is provided in the clinics, this 
could provide support for setting up more clinics within both primary and secondary 
care settings. Reports on pharmaceutical care needs can allow strategic planning of 
services to patient subgroups with the highest pharmaceutical care needs.  
       
6.4.2 Categorisation of pharmaceutical care issues in clinical practice 
In a busy clinical practice it can be difficult to make time to categorise care issues in 
addition to carry out all of the usual tasks. A categorisation system should therefore 
be easy to use, it should be fast and it should reflect reality. The first impression of 
the categorisation system used in this study is that it at first can seem complex and 
difficult to use straight away. It would therefore be difficult to get good inter-rater 
reliability when first starting to use the system. This obstacle could be managed by 
having peer review meetings where one could discuss how the different pharmacist 
would categorise different care issues. Over time this would facilitate increased 
consistency in the use of the categorisation system. Eventually, increased familiarity 
with the system would also make it easier and quicker to use in clinical practice. 
Auditing of practice would then not be depending on students coming in to do the 
work periodically. Another benefit of self auditing is that the pharmacists know each 
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patient and their pharmaceutical care issues well. The standard of documentation 
would then not influence the outcome of the audit.  
 
Implementation of self auditing of practice would take time. Every pharmacist have to 
be equally involved in the work, the methods that are going to be used have to be 
clear and consistent and the results have to be followed up. Auditing is of no benefit if 
there is no evident point of why it is executed. One possible negative side of self 
auditing could be the risk of bias if the results are an overestimate of the pharmacists’ 
true contribution to the pharmaceutical care delivery. This would be an argument for 
having an independent data analyst coming in to conduct the audit. 
 
6.5 Future work and unanswered questions 
 
As a natural part of the audit cycle the results from the evaluation of the 
pharmaceutical care delivery needs to be presented to the Lothian Managed Clinical 
Network through Lothian Diabetes Service Advisory Group (LDSAG) following review 
by the Pharmacy Diabetes Strategy Group.  
 
Populating the database with more patients will allow assessment of pharmaceutical 
care needs for different patient populations e.g. diabetes ethnic minority patients. An 
audit comprising all of the DCVR clinics could provide information on if the 
pharmaceutical care provided is consistent. Since this project clearly demonstrated 
lack of documentation in the pharmaceutical care plans, it would be interesting to do 
an audit comparing retrospectively and prospectively collected pharmaceutical care 
issues. This will make it possible to assess if the level of documentation has been 
improved and/or highlight the areas which still needs improvement. 
 
Audits of the pharmaceutical care delivery need to be done periodically to ensure that 
the proposed changes have been implemented, and that the pharmaceutical care of 
the patients has been improved. This is the only way to reach a higher level of quality 
of care. 
 
The patients gets close follow-up of their treatment by the pharmacist when they 
attend the clinics, and after discharge the pharmaceutical care of the patients is the 
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GP`s responsibility. It is therefore a need to ensure continuity of pharmaceutical care 
after discharge. Due to the new community pharmacist contract for management of 
chronic diseases 11, community pharmacists are expected to provide a specified level 
of pharmaceutical care. The medication assessment tool can be used to characterise 
and quantify pharmaceutical care issues outstanding in patients discharged from the 
DCVR clinic. This information can be used to develop documentation which can be 
used in the discharge process from the DCVR clinics.   
 
The database has to be tried out in practice by the DCVR clinical pharmacists. 
Feedback after the trial period will provide information on any necessary changes 
that has to be made in order to make it more easy to use, able to generate more 





By conducting an audit of the pharmaceutical care delivery at three of the DCVR 
clinics, a profile of the care provided was made. The results showed little contribution 
by the pharmacists in some areas of the pharmaceutical care delivery, suggesting 
lack of pharmacist documentation. This was acknowledged by the DCVR 
pharmacists in the focus group meeting as the reason for the discrepancy from 
clinical practice.  
 
The standard of pharmacist documentation has to improve for pharmacists to prove 
their worth. A database, as developed in this project, would greatly help to achieve 
that. Further refinement of the instrument is likely to improve the ease of use and 
minimize the time required for entering in data. Populating the database with more 
patients will make it possible to use as a tool to identify pharmaceutical care needs 
and help in strategic planning of services. 
 
Clinical audit is a valuable tool to ensure continuous quality improvement in the 
management of diabetes patients with high cardiovascular risk. The results from this 
audit served as a prompt for the DCVR clinic pharmacist in how to best provide the 
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Appendix 1: Diabetic Cardiovascular Risk Clinic - Patient Care Plan 
 
















Weight: _____________  Target weight:_____________  BMI:_______________ 
 
Smoker:  ⁪ Yes ⁪ No  If yes (______ cigarettes /day) Ex-smoker:  ⁪ Yes ⁪ No    Date stopped:__________ 
 
Alcohol: ⁪ Yes ⁪ No  Units per week: ____________ Advice:____________________________________________. 
. 
Exercise advice: _______________________________ Conditions limiting exercise: ____________________________ 
 
Diet advice ________________________________________________________________ Referred to dietician ⁪ Yes⁪ No 
 











Referral Information including Relevant Medical History: 
Date Previous Drug therapy  Pharmaceutical Issues 
  
   
 
 
Medication checked and verified by:            SCI-DC            GP Letter         GP practise                Patient                 Patients own drugs               Repeat Prescription               
(Please circle)                                                            
                                                                                   Other __________________________ 
 
Date of first visit:   
   _______________ 
 
Referral BP:   _______________ 
 






Cardiovascular medicines (antihypertensives, lipid lowering agents, antiplatelet agents) 





Medication Dose/Directions Stop Indications/Comments 
     
     
     
     
     
     
     
     
     
     
     
 
Date 
         
eGFR          
Creat (55-150 µmol/l)          
Urea  (2.5-6.6 mmol/l)          
Urine ACR          
Na (132-144 mmol/l)          








Gluc (3.6-5.8 mmol/l)          
Total chol          
HDL          
LDL (<2mmol/L)          





Total/HDL (<4 mmol)          
ALT (10-40 u/l)          
ALB (36-47g/l)          




GGT (5-35 u/l)          
CK          





          
Start 
Date 
Medication Dose/instructions Stop Indication/comments 
(can medication increase blood 
pressure/cholesterol) 
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Patients Name:__________________ 
Patient admitted to clinic on what step of treatment process:________________________________ 
 
Note: If the patients’ treatment is not following the step-wise process e.g. patient starting treatment at step 4, 
then any medication to be added should be done so starting at step 1 and continued according to the clinic 
guidelines. 
 




 Drug Name 
(Please tick the box 
if already on/tried 


















Interventions / Comments 

























Max 300mg  
 
Date:____________ 
   After 2 wks   
Bendroflumethazide 
























Amlodipine 5mg  
Increasing to 10mg 
OD after 4-6weeks 
 
Date:____________ 





 Atenolol 50mg  
 
Date:____________ 








Increasing to 50mg 
then 100mg as 
necessary  
       
Date:____________ 







Increased to 2mg OD 
after 1-2 wks then 
4mg, 8mg and  MAX 
16mg  
Date:____________ 




CARE ISSUE: To ensure that patients who are candidates for ANTIPLATELET THERAPY receive  
appropriate treatment. 
Indications for use: 
 
All patients with diabetes should be on anti-platelet therapy unless contraindicated, once BP is relatively controlled (< 160/90 mmHg), due to 
10 year risk of CVD > 20%.  
 
 
CARE ISSUE: To ensure that patients who are candidates for LIPID LOWERING THERAPY receive 
appropriate treatment. 
Indications for use: 
 








(Please tick the box if already 
on/tried this drug) 
Any C/Is 
Any S/Es Treatment  started? Y/N 
Step 1: Aspirin 75mg daily 
 
Date:____________ 
Unstable BP or BP > 150/90 mmHg   
Step 2: Aspirin + PPI 
 
Date____________ 
Unstable BP or BP > 150/90 mmHg   
Step 3: Clopidogrel 75mg 
 
Date____________ 
   
Drug Name 
(Please tick the box if already 
on/tried this drug) 






LFTs and Chol checked 
after 
2-3 months 
Target Reached – Y/N 
If no go next step 
Step 1: Simvastatin  20/80mg 
daily  
Date____________ 
     
Step 2: Atorvastatin 10–80mg 
daily  
Date____________ 
     
Step 3: Other  statin 
 
_________________________ 
     
Other: 
Combined Statin and Fibrate 
 
______________________ 
     
High Triglvcerides Any C/Is? renal impairment* 
Any S/Es Treatment Started? – Y/N 
Fenofibrate 
(Lipantil micro 267)  
Date______________ 
   





Notes and Interventions: 
 
                                                                                                                                                                                       Letter to GP   

















Letter to GP  
BP U+E’S Smoking /Alcohol Exercise / Diet Compliance GP accepted 
advice 
Pt taking new 
Rx 
       
 












Letter to GP  
BP U+E’S Smoking /Alcohol Exercise / Diet Compliance GP accepted 
advice 
Pt taking new 
Rx 
       
 











Letter to GP  
BP U+E’S Smoking /Alcohol Exercise / Diet Compliance GP accepted 
advice 
Pt taking new 
Rx 
       
 











                                                                                                                                                                                                     
                                                                                                                                                                                 Letter to GP  
BP U+E’S Smoking /Alcohol Exercise / Diet Compliance GP accepted 
advice 
Pt taking new 
Rx 
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Appendix 2: PHARMACEUTICAL CARE PLAN: TYPE 2 DIABETES 
PATIENT PROFILE 
(Patient label)   
 Name 
  CHI # Gender 
  
 Male  
 
 




























Date of birth/ Age 




Drug sensitivities  
DepCat Date diagnosed 
 
Occupation Number/day:  
Vaccines:                                          Date 


























Black    
Asian     





   
 
    
Alcohol consumption  
Y     N  
Units/week: 
Comment 
Limitations/Special needs        Annual Review:         GP/ Hospital 
                            Date Attended      Date Due              Comment 
                  Sight   Hearing   Speech  Language   Physical   Other Eye   
Foot   Comment  
Renal   
 
History of complications   







DIABETES TREATMENT (PAST AND CURRENT) 
Medication Start                                        Stop Reason Medication Start                                        Stop Reason 
        
        
        
        
 
CARDIOVASCULAR HISTORY AND CURRENT MEDICINES 
       Hypertension  Stroke/TIA    IHD   [Angina  MI   ]  Angioplasty     CABG  PVD     Other 
































































tolerated?         
 















OTHER MEDICAL HISTORY 
                                                                                              Date             
Date 
OTHER DRUG HISTORY (including OTC) 
                                               Date                                                               Date 
        
        
        






Care Episode 1 
Date:  
Values               Date 
Care Episode 2 
Date: 
Values               Date 
Care Episode 3 
Date: 
Values               Date 
Care Episode 4 
Date: 
Values           Date 
Care Episode 5 
Date: 
Values               Date 
Care Episode 6 
Date: 
Values               Date 
HbA1c (%)                                
TC (mmol/L)             
HDL (mmol/L)             
LDL (mmol/L)             
TG (mmol/L)             
TC:HDL             
K (mmol/L)             
Blood pressure (mmHg)             
LFTs              ALT/AST             
Creatinine  (µmol/L)             
Microalbuminuria    
(M: ACR >2.5mg/mmol) 
(F: ACR > 3.5mg/mmol) 
            
Proteinuria 
(ACR>30mg/mmol) 






     
EDUCATIONAL NEEDS ASSESSMENT Date of assessment:                                              
General advice Self-medication Self-management Self-management Assessment 
Diabetes  Oral agent timing  Glucose monitoring  Concordance           (min) +     ++   +++ (max)   











 Dexterity                             (min) 1  4 (max) 
Diabetes control  Insulin administration  Hypos  
Complications  Injection sites  Foot care  
Diet/Exercise  Insulin compliance  Intercurrent illness  
Smoking 
cessation 
 Written information on 
medicines 













Patient Education / Documentation 
changes and Therapeutic Plan Checks 
Therapeutic Plan Changes 
(Individualisations/ Dosage change/  Treatment interruption/ 








































































































































Appendix 3: GUIDELINES FOR CATEGORISATION OF CARE ISSUES 
1. Introduction…………………………………………………………………………………1 
2. Definition of a pharmaceutical care issue……………………………………………….2 
3. The categorisation system – a short summary…………………………………………2 
4. ‘Check’ and ‘Change’ categories…………………………………………………………3 
4.1. Checks………………………………………………………………………………...3 
4.2. Changes………………………………………………………………………………4 
5. Change in Drug Therapy Process……………………………………………………….4 
5.1. Explanation of the Change in Drug Therapy Process subcategories……..5 
6. Change in Drug Therapy...........................................................................................6 
7. Drug Therapy Problems...................................................................................……..7 
8. Quality Assurance Descriptors………………………………………………………….10 
8.1. Time Perspective…………………………………………………………………...11 




1. The care issue is found not to be an actual or potential drug therapy problem 
that needs further follow up at this point 
2. There is an identified need to take action(s) to prevent future drug therapy 
problems. 
3. A drug therapy problem is identified and there is a need for a change in the 
patient’s drug therapy at this point  
 
 
Pharmaceutical care is delivered by a team of health care professionals. The focus of 
the categorisation system described here is pharmaceutical care contributions made 
by the pharmacist within that context.  
 
To better comprehend this guideline it is important to have an understanding of how 
the pharmacist provides pharmaceutical care. This is a cyclical process and will 
briefly be described here. 
 
The pharmacist initiates this process by gathering relevant information about the 
patient’s drug treatment and medical history, which reveals pharmaceutical care 
issues. The pharmacist handles the care issues by doing checks leading to three 




2 Definition of a pharmaceutical care issue 
 




(1) As either a Check or a Change1; where a Change may be a Change in the Drug 
Therapy Process or a Change in Drug Therapy, depending on the outcome.  
 
The care issue is further categorised into 
 
(2) Quality Assurance (QA) Descriptors1, which indicate a care issue’s position in the 
process of delivering pharmaceutical care. If the care issue is a Change in Drug 
Therapy this category also describes the extent of the change made.  
 
The third dimension in the system is  
(3) Drug Therapy Problem2 and only a care issue identified as a Change in Drug 
Therapy will be categorised as such. 
 
If the outcome of the care issue is unknown, the care issue is incomplete and can not 
be categorised in the categorisation system.   
 
A pharmaceutical care issue is an identified concern regarding a potential or actual 
drug therapy problem. A drug therapy problem is patient specific, and so does not 
include non-adherence to local formulary choices that are based on cost controls. 
The categorisation system is developed to describe pharmaceutical care. This is 
done by analysing each care issue and assigning them into categories. This 
categorisation process provides a basis for quantitative description of the 
pharmacist’s contribution to pharmaceutical care, which makes it possible to compare 
pharmaceutical care provided by a pharmacy service across different settings. 
Each care issue is described according to a triangularised system which consists of 
multiple categories. The advantage of combining different categorisation systems into 
one triangularised system is that the categories supplement and support each other, 
and therefore they capture the different dimensions of the pharmaceutical care 
issues.  
 
Each care issue is categorised in three such dimensions; 
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Table 1. Categorisation set-up 
Quality Assurance 
Descriptors 












       
4 ‘Check’ and ‘Change’ categories 
 
4.1 Checks  
If the pharmacist recommends making a change in the patient’s drug therapy in order 
to resolve or prevent a drug therapy problem, but the responsible prescriber either 
doesn’t agree with the change or agrees but forgets to make it, the care issue will be 









When a care issue is identified, the pharmacist has to perform checks in order to 
detect required actions to prevent future drug therapy problems or required changes 
in drug therapy addressing actual drug therapy problems. If the check leads to 
neither an action nor a change the care issue is categorised as a Check. A care issue 
categorised as a Check is assigned to one of four subcategories; “medication needs”, 
“effectiveness”, “safety” or “compliance”, based on the reason for the inquiry as 
summarised in table 2.  
 
The pharmacist’s intentions behind making the check constitute the basis for the 
number of care issues identified and for the categorisation of the identified check(s). 
A check performed by a pharmacist may be an inquiry which addresses both 
effectiveness and safety, (for instance when INR or lying/standing blood pressure is 
measured). In that case the care issue will be divided into two care issues; one check 














5 Change in Drug Therapy Process 
 
Table 2. Check 
Check Code 
Medication need inquiry MED 
Effectiveness inquiry EFF 
Safety inquiry SAFE 
Compliance inquiry COMP 
 
The category Change is divided into two types of subcategories; Change in Drug 
Therapy Process and Change in Drug Therapy. The Change in Drug Therapy 
Process category includes care issues relating to changes in the care process, and 
this means that the impact of the outcome often is hard to determine or is too 
speculative to lead to a Drug Therapy Problem category. The Change in Drug 
Therapy category, on the contrary, includes changes related to drug therapy, non-
compliance and prescription, where the outcome can be assigned a recognisable 
Drug Therapy Problem category. 
 
Even though all changes are inevitably the result of a check, such checks will not be 
categorised since their relevance is superseded by the resulting change. The care 
issue will be adequately described by the resulting categories of Change, Quality 
Assurance Descriptors and Drug Therapy Problem. 
 
 
The pharmacist performs different actions to address the pharmaceutical care needs 
of the patient. Not all of these actions result in a change to the patient’s drug therapy. 
Nevertheless it is important that these actions are quantified, as they comprise a 
great part of the pharmacist’s delivery of pharmaceutical care.  
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The category Change in Drug Therapy Process describes the actions the pharmacist 
performs to prevent potential drug therapy problems and to identify actual drug 
therapy problems (Table 3).  
 
Table 3 Change in Drug Therapy Process categories 
Changes made to Code 
Clinical (shared) record of patient characteristics CHAR 
Clinical (shared) record of drug history DH 
Continuity of information/care between clinical settings CONT 
Level of patient monitoring MON 
Health care team member(s) information/education INF 
 
 
5.1 Explanations of the Change in Drug Therapy Process subcategories 
 
Clinical (shared) record of patient characteristics  
This and the next subcategory describe actions that may affect the patient’s drug 
therapy since his/her treatment is based on available patient information. For 
instance, it is important to note in the patient’s record if he/she is allergic to 
penicillins, in case an antibiotic treatment is required later. These actions help to 
avoid potentially preventable drug therapy problems in the future.  
 
If the pharmacist corrects or up-dates the patient’s shared records, for instance adds 
two drugs that the patient is allergic to, this will be recognised as one care issue. If 
drug therapy changes have to be made as a result of the corrected or up-dated 
record, this is recognised as one care issue for each drug that is changed.  
 
Clinical (shared) record of drug history  
When the pharmacist takes the drug history, discovers errors in prescribing on 
admission and proposes/makes a change to the drug therapy based on this, this is 
interpreted as one pharmaceutical care issue for each drug that is changed.  
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Continuity of information/care between clinical settings 
This subcategory encompasses the actions the pharmacist undertakes to ensure 
continuity of care and transfer of relevant information between clinical settings, 
including making new arrangements for the patient with other health care institutions.  
The clinical settings include all healthcare institutions that have responsibility for the 
patient’s health care.  
 
A number of care issues might be included globally in a document transferring the 
patient’s care between clinical settings. If the pharmacist prepares or advises on the 
document, but doesn’t follow-up on the recommendations made, that would be a 
single care issue. This is because the care issues have unknown outcomes, and 
therefore can’t be categorised. We can only categorise the action of the pharmacist in 
terms of making the recommendation. 
 
Level of patient monitoring 
Some care issues can result in the identification of a need to increase/improve 
patient monitoring.  This increased/improved patient monitoring doesn’t have to be 
performed by the pharmacist, but he/she must initiate it or advice about it. 
 
Health care team member(s) education / information 
 
6 Change in Drug Therapy 
 
• the drug therapy of the patient 
• the patient/patient’s carer understanding of the drug therapy or disease  
• the patient’s adherence to their treatment plan, that is patient compliance   
This subcategory describes care issues where the pharmacist contributes by 
providing information or education to other health care personnel regarding the 
patient’s drug therapy. 
A care issue that is categorised as a Change in Drug Therapy (Table 4) includes 
changes to;  
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The outcome of changes made to the patient/carer understanding/compliance is hard 
to measure, but it is included in the Change in Drug Therapy subcategory because it 
can be categorised as a Drug Therapy Problem, and it can be viewed as a 
categorisation of the intention of the effort made by the pharmacist. 
 





7 Drug Therapy Problems (DTP)  
The categories of Drug Therapy Problems are those defined in the book 
Pharmaceutical Care Practice – The Clinician’s Guide 2 by Cipolle et al. The 
categories are given examples here to include a broader range of care issues. In 
addition they are modified to enhance the correlation between the heading of the 
DTP subcategories and the type of care issues included in them. An additional 
subcategory Unclassified has been added in order to categorise care issues where 
the change is not patient specific. For instance due to non-adherence with local 




Pharmacists, unless they are acting as prescribers themselves, will in most cases 
make a recommendation to the patient’s prescriber, and the care issue will be 
categorised as a Change in Drug Therapy if the recommendation is accepted and 
carried out.  
Changes made to: Code 
Drug selection (starting new or changing drug) SEL 
Dose  DOSE 
Route/dose form FORM 
Dose interval/timing INT 
Duration DUR 
Stop drug temporarily/permanently STOP 





Only Change in Drug Therapy types of care issue will be categorised into Drug 
Therapy Problem categories. The combination of the Change in Drug Therapy 
subcategory and the Drug Therapy Problem subcategory will describe the nature of 
the change made to the patient’s drug therapy, see table 5 below. 
 
Table 5. Categories and common causes of drug therapy problems 
Drug Therapy Problem        Common causes of drug therapy problems 
 

















There is no valid medical indication for the drug therapy at this time 
 
Multiple drug products are being used for a condition that requires 
fewer drug therapies 
 
The medical condition is more appropriately treated with non drug 
therapy 
 
Drug therapy is being taken to treat an avoidable adverse reaction 
associated with another medication 
 
Drug abuse, alcohol use, or smoking is causing the problem 
 
The duration of therapy is too long 
 











A medical condition requires the initiation of drug therapy 
 
Preventive drug therapy is required to reduce the risk of developing 
a new condition 
 
A medical condition requires additional pharmacotherapy to attain 
synergistic or additive effects 
 
The duration of drug therapy is too short to produce the desired 
response 
 












The drug is not the most effective for the medical problem 
 
The medical condition is refractory to the drug product 
 
The dosage form of the drug product is inappropriate 
 
The drug product is not an effective product for the indication being 
treated 
 
The time of dosing or dosing interval is not the most effective 
 
Route of administration is not the most effective 
 







The dose is too low to produce the desired response 
 
The dosage interval is too infrequent to produce the desired 
response 
 
A drug-drug/food/lab/disease interaction reduces the amount of 




Table 5 (cont.) Categories and common causes of drug therapy problems 



















The drug product causes an undesirable reaction that is not dose-
related 
 
A safer drug product is required due to risk factors 
 
A pharmacodynamic drug-drug/food/lab/disease interaction causes 
an undesirable reaction that is not dose-related  
 
The dosage regimen was changed too rapidly 
 
The drug product causes an allergic reaction 
 
The drug product is contraindicated due to risk factors 
 
The time of dosing or the dosing interval is not the safest. 
 
Route of administration is not the safest 
 









Dose is too high 
 
The dosing frequency is too short 
 
A drug-drug/food/lab/disease interaction occurs resulting in a toxic 
reaction to the drug product 
 


















The patient prefers not to take the medication 
 
The patient does not understand the instructions 
 
The patient forgets to take the medication 
 
The drug product is too expensive for the patient 
 
The patient cannot swallow or self-administer the drug product 
appropriately 
 
The drug product is not available for the patient 
 














8 Quality Assurance Descriptors 
 
A patient’s drug treatment can be regarded as a cyclical process, which 
encompasses the design, delivery and evaluation of the treatment plan according to 
expectations predefined by clinical standards. Figure 1 shows the pharmacist’s 
systematic role as a contribution to increase the quality of this cyclical process. At 
each step during the cycle the pharmacist (and other health care team members) is 
in a position to perform checks to confirm the quality of the delivery of the treatment 
plan. Whenever the checks reveal deviations from the expectations established in the 
plan, changes to the treatment or the treatment plan are proposed or executed. This 
process can be viewed as a feedback loop, where changes are integrated into the 
cycle.  














Figure 1 Pharmaceutical care model  
 
The Quality Assurance (QA) Descriptors identify both the points in the feedback loop 
at which the care issues (the Checks or Changes) are implemented and the extent of 
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changes in drug therapy. To emphasise what they describe, the subcategories for QA 
Descriptors are designated Time Perspective and Degree of Change. 
 
All care issues will be categorised according to the QA Descriptor Time Perspective. 
This QA Descriptor adds a time perspective in the treatment cycle to the 
triangularised system. If the care issue is a Change in Drug Therapy it will be 
categorised according to the QA Descriptor Degree of Change as well. This QA 
Descriptor describes the extent of the change made (Table 6).  
 
Table 6. Summary of which care issues are categorised into the two different 
Quality Assurance Descriptors subcategories 
Quality Assurance Descriptors 
Time Perspective Degree of Change 
 
Check 
Change in Drug Therapy Process 
Change in Drug Therapy 
 
Change in Drug Therapy 
 
 
8.1 Time Perspective 
 
Table 7. Categorisation of checks according to quality system feedback loop 






medications in the 




Checks at the start of the treatment to make sure that, for 
each medicine, the patient: 
- is on the right medicine 
- is on the right dose 
- is not on unnecessary medication 
- doesn’t have any new needs for additional medication 
- is not receiving a combination of interacting medicines 
- understands how to take their medication and what it will 
do to them 
The subcategories of Time Perspective are Verification, Monitoring and 
Confirmation, see table 7.  These subcategories relate to the point in the system 







treatment is appropriate 






Checks as treatment continues which should ensure that, 
for each medicine, the patient: 
- is on receiving medication as intended 
- continues to be on the most suitable dose 
- has no symptoms of unwanted(adverse) effects 




Checking that medication 






Confirmation and documentation to identify that 
medication is: 
- resulting in expected effects on the patient's condition 
- not failing to control condition 
- not producing unwanted effects requiring clinical review. 
 
Verification  
A ‘Verification’ is either done at the start of a new patient treatment or when the 
pharmacist first assesses the patient and the medication, see table 7. 
 
• In chronic disease management, for instance by a clinical pharmacist at an 
outpatient clinic or a community pharmacy, ‘Verification’ is done at the first 
episode of care with the pharmacist. That may or may not be at the start of the 
patient’s treatment but must be undertaken for the pharmacist to assure himself or 
herself that the proposed treatment plan is suitable for the patient’s need.  
• When the patient is seen in an interim episode of care interrupting chronic 
disease management, for instance by a clinical pharmacist at a hospital ward 
during an acute admission, the verification category will relate to when the 
pharmacist first saw the patient. ‘Verification’ of the patient’s drug treatment is 
done at admission, or when a new drug is started. All checks at this point in care 
should be categorised as ‘Verification’ even if the treatment has been going on for 





‘Monitoring’ is done during the patient’s treatment (during the delivery of the 
treatment plan) with the goal of assuring the medication process is being 
implemented as intended and within general expectations of signs of benefits 




8.2 Degree of Change 
 
The Degrees of Changes are Adjustment, Modification and Prompt a Review, see 
table 8. These three subcategories describe the extent of the change made. Both 
Adjustment and Modification may take place at the start or during treatment, while 
Prompting of a Review results from a failure in treatment and so only occurs after a 
trial period of treatment, see figure 1. 
 
Since it is difficult to distinguish between the extents of changes made in Change in 
Drug Therapy Process, only Change in Drug Therapy will be categorised into Degree 
of Change.  
 
Table 8. Categories of changes according to the extent of the change in the quality 
system feedback loop 
 
Degree of Change Code 
Adjustment ADJ 
Modification MOD 
Review (prompt a review) REV 
 
If a Check leads to a Change, the Time Perspective (i.e. at what time in the treatment 
cycle the check is done) will influence the choice of the subsequent Degree of 
 
‘Confirmation’ is an evaluation of the patient’s treatment to assure that expected 
effects are achieved, adverse effects avoided or suitably managed and that the 
condition is treated optimally, see table 7. This category usually applies to care 
issues concerning the continuing evaluation of a chronic disease, an acute 
exacerbation of a chronic disease, or an acute episode of disease 
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Change. As seen in figure 1 and table 9, a Verification can lead to either an 
Adjustment or a Modification. A Monitoring issue can only lead to an Adjustment. 
If a need for a bigger change in the treatment is identified, a Confirmation of the 
whole treatment of the patient is needed before a decision to either ‘modify’ or 
‘review’ the treatment can be made. A Confirmation can lead to either a 
Modification or a Review, depending on the outcome of the ‘confirmation’. 
 
Table 9. Categories of changes according to the time aspect in the quality system 
feedback loop, linked to preceding check 
 
Time Perspective Code Degree of Associated Change 
Verification VER ADJ MOD 






Adjustment is defined as a recommended change to patient behaviour, treatment 
regimen or process of continuity of care that individualises pharmaceutical care within 
the agreed treatment plan. ‘Adjustments’ are anticipated within the protocol/clinical 
management plan, and the regimen is not markedly changed to an alternative 
treatment regimen. Most supplementary prescribing decisions made by pharmacists 
would probably fall into this category. 
 
Modification 
Modification is a change to the patient treatment that is not anticipated and leads to 
a change of the patient’s treatment plan.  
 
Prompt a Review    
A Review is a re-assessment of the patient’s treatment, and leads to a change in the 
expectations defined by clinical standards i.e. change in the expectations to the 
outcome of the treatment. Because the pharmacist is not able to review the treatment 
alone, but has to recommend a review to the patient’s main prescriber, the qualified 
term category is termed ‘Prompt a Review’. ‘Prompt a Review’ is done as a part of 
the evaluation of the patient’s treatment. This will be done more often in an outpatient 




1. Hudson SA, McAnaw JJ, Johnson BJ. The Changing Roles of Pharmacists in 
Society. IeJSME. 2007; 22-34 
2. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice. The clinician’s 
guide. 2nd ed: McGraw-Hill; 2004 
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Appendix 4: MAT for patients with chronic cardiovascular disease 
 Qualifying criteria  Standards 
1i Current smoker Invited to join smoking cessation programme 
2ii Diagnosis of hypertension (HTN) Prescribed antihypertensive therapy  
3i,iii Diagnosis of cardiovascular disease (CVD) Prescribed a statin 
4i,3 Patient without CVD who complies with at least one of the following: Aged >40 and 
estimated 10 year CVD risk ≥20%, aged >40 and Diabetes Mellitus (DM), familial 
hypercholesterolaemia 
Prescribed a statin 
5 Diagnosis of  cardiovascular disease (CVD) and prescribed a statin Prescribed simvastatin at a dose of at least 40mg or equivalent dose of alternative 
statin or a documented maximum tolerable statin dose 
6 Patient without CVD and aged >40 and estimated 10year CVD risk ≥20% and prescribed 
a statin 
Prescribed simvastatin at a dose of at least 40mg or equivalent dose of alternative 
statin or a documented maximum tolerable statin dose 
7 Prescribed a statin and an interacting drug Prescribed an acceptable statin or acceptable dose labelled as acceptable on 
specified list 
81 Prescribed a statin TC ≤ 4mmol/L 
93 Diagnosis of cardiovascular disease (CVD) Prescribed aspirin 75 mg 
103 Patient without CVD and without DM but estimated 10year CVD risk ≥20% Prescribed aspirin 75 mg 
11iv Patient without CVD and WITH DM, who complies with at least one of the following: 
DM diagnosed ≥10 years ago, prescribed antihypertensive drug therapy, retinopathy, 
nephropathy  
Prescribed aspirin 75 mg 
122 Prescribed aspirin Achieved a blood pressure of ≤ 150/90mmHg 
13v Patient with a history of acute ischaemic stroke or transient ischaemic attack (TIA)  Prescribed a combination of aspirin (75-300 mg daily) plus dipyridamole (200 mg 
twice daily)  
14vi Patient with CVD who complies with at least one of the following: History of acute 
ischaemic stroke or TIA while on a combination of aspirin/dipyramidole therapy, 
contraindication/intolerance to aspirin 
Prescribed clopidogrel at a dose of 75mg instead of aspirin 
153,4,6 At least one of the following: DM, stable angina, diagnosis of heart failure (HF) Prescribed an ACE inhibitor 
166 NO diagnosis of HF, Diagnosis of DM, overweight and prescribed an oral 















Prescribed metformin  
DIAGNOSIS OF HYPERTENSION, PRESCRIBED ANTIHYPERTENSIVE THERAPY…  
172 … and at least one of the following: diagnosis of CVD, DM, chronic renal failure Achieved a blood pressure of ≤ 130 systolic AND ≤ 80mmHg diastolic 
182 … and NONE of the following: diagnosis of CVD, DM, chronic renal failure Achieved a blood pressure of ≤ 140 systolic  AND ≤ 85 mmHg diastolic 
193 … and prescribed a single antihypertensive agent and at least one of the following: gout,    
     poor renal function, current hypokalaemia, dyslipidaemia 
Prescribed a  calcium channel blocker or ACE- inhibitor 
DIAGNOSIS OF HYPERTENSION, PRESCRIBED ANTIHYPERTENSIVE THERAPY AND DOES 
NOT HAVE A DIAGNOSIS OF CVD OR CHRONIC HEART FAILURE… 
 
203 … and < 55 years old and non-black  Prescribed an ACE inhibitor 
213 … and < 55 years old and non-black and an apparent contraindication or   
     intolerance to an ACE inhibitor 
Prescribed an AII antagonist 
222 … and at least one of the following: >55 years old, black Prescribed a thiazide diuretic or calcium channel blocker  
232 …  NOT prescribed a combination of a thiazide diuretic and a BB 















Drugs on specified list are avoided * 
DIAGNOSIS OF ANGINA…  
25viii … (not Prinzmetal angina) Prescribed a beta-blocker 
268 … and NO heart failure AND apparent contraindication or intolerance to a beta-blocker  Prescribed a rate limiting calcium channel blocker, long acting nitrates or nicorandil 
278 … and heart failure AND apparent contraindication or intolerance to a beta-blocker  Prescribed a long acting nitrate or nicorandil 
288 … Prescribed sublingual glyceryl trinitrate or glyceryl trinitrate spray 
298 …and NO heart failure and prescribed a beta-blocker AND a second agent for control of 
angina symptoms 
Prescribed a calcium channel blocker 
308 … Patient with stable angina and heart failure prescribed a beta-blocker AND a second 
agent for control of angina symptoms 
Prescribed amlodipine or felodipine 
318 … and prescribed regular nitrate Uses a dosage regimen which avoids the development of tolerance    
328 … and a history of MI without heart failure and prescribed one of: captopril (C), enalapril 





Prescribed target dose (C 50mg bd, E 20-40od, L or R 10mg od) or a documented 
maximum tolerated dose 
DIAGNOSIS OF CHRONIC HEART FAILURE…  
33ix … and prescribed one of the following: captopril (C), enalapril (E), lisinopril (L), perindopril 
(P), ramipril, (R) or trandolapril (T) 
Prescribed target dose (C 50 mg tds, E 10-20 mg bd, L  20mg od,  R 10 mg od, P 8 
mg od or T 4mg od) or a documented maximum tolerated dose 
349 … Drugs on specified list are avoided # 
359 … and NOT prescribed an ACE inhibitor Prescribed an AII antagonist 
369 … mild to moderate or moderate heart failure and prescribed target or maximum tolerable 
doses (if less) of an ACE-Inhibitor and betablocker and remains symptomatic 
Prescribed candesartan 
379 … and not prescribed an ACE inhibitor or AII Antagonist  Prescribed a combination of hydralazine and ISDN   
389 … and prescribed Losartan (L), Candesartan (C), Valsartan (V) Prescribed target dose (L 50mg od, C 32mg od, V 160mg bd) or a documented 
maximum tolerated dose 
399 … Prescribed a beta blocker (except metoprolol tartrate) 
409 … on Carvedilol (C), Bisoprolol (B) or Nebivolol (N) 
 
Prescribed target dose (C 25-50mg bd, B or N 10od) or a documented maximum 
tolerated dose  
419 … and symptoms of heart failure Prescribed diuretic treatment 
429 … moderate or moderate to severe heart failure and prescribed target or maximum 
tolerable doses (if less) of an ACE inhibitor and beta  blocker  and  remains symptomatic 
Prescribed spironolactone 
439 … moderate or moderate to severe heart failure and prescribed target or maximum 
tolerable doses (if less) of an ACE inhibitor and beta  blocker and remains symptomatic 
and developed gynaecomastia 
Prescribed eplerenone 
449 … and a history of MI and at least one of: HF symptoms or diabetes  Prescribed eplerenone 
459 … and on spironolactone (S) or eplerenone (E) Prescribed target dose (S 25- 50mg od, E 50mg od) or a documented maximum 
tolerated dose 
469 … without AF and with current symptoms of heart failure despite optimal therapy  Prescribed digoxin 
479 … Receives an annual influenza vaccination 
489 … Received a once-only pneumococcal vaccination 

























*   Corticosteroids (except inhaled or topical), sympathomimetics (except inhaled beta 2- agonists), oral contraceptives, Monoamine-
oxidase inhibitors, NSAIDS (except aspirin as an antiplatelet), 
     carbenoxolone, high sodium-containing products eg. effervescent formulations, certain antacids, liquorice 
 
#
   Class I+III antiarrhythmics (except amiodarone), Verapamil and diltiazem, Calcium channel blockers (except amlodipine and 
felodipine), Minoxidil, Oral corticosteroids. NSAID’S (except aspirin as an  
     antiplatelet), Metformin, Thiazolidinediones (glitazones), Tricyclic antidepressants, Itraconazole, Fluconazole, Voriconazole, 




1 Scottish Intercollegiate Guidelines Network (SIGN). Prevention of coronary heart disease (latest draft Draft May/June 2006) 
 
1 British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004;328; 634-640. 
 
1 British Hypertension Society and National Institute for Health and Clinical Excellence. Clinical Guideline 34: ‘Hypertension: management of  
  hypertension of adults in primary care: partial update. June 2006 
 
1 Joint British Society’s guidelines on prevention of cardiovascular disease in clinical practice: summary 12/2005 
 
1 National Institute for Health and Clinical Excellence. Clopidogrel and modified release dipyridamole in the prevention of vascular occlusive   
  events. Technology appraisal 90. May 2005. Accessed from nice.org.UK on 25/05/06 
 
1 Scottish Intercollegiate Guidelines Network (SIGN) Publ. No. 55. 
 
1 Scottish Intercollegiate Guidelines Network (SIGN) Publ. No. Hypertension in older people. 
 
1 Scottish Intercollegiate Guidelines Network (SIGN) Publ. No.SIGN 51. Management of stable angina. April 2001 
 
1 Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. (latest draft May/June 2006)  
 
1 Scottish Intercollegiate Guidelines Network (SIGN). Arrhythmias associated with chronic coronary artery disease/left ventriczular dysfunction   
   (latest draft May/June 2006) 
 









PATIENT WITH ATRIAL FIBRILLATION  …  
5010 … and without heart failure and AF is well-tolerated   Prescribed either a beta-blocker, verapamil, diltiazem or digoxin 
5110 … and at least one additional risk factor for thromboembolism Prescribed warfarin 
5210 … and at least one additional risk factor for thromboembolism (aged >75 years, or >60 
years with other risk factors such as hypertension, DM, or left ventricular dysfunction) and 




Is prescribed Antiplatelet therapy   
PATIENT PRESCRIBED WARFARIN…  
53xi … INR measured at intervals of which none > 12 weeks 
5411 … and warfarin dose changed INR measured within 1 week after dose change or starting each drug 











INR history with at least 60% of INRs within target range 
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Living alone………..           
Living with partner/ 
Family………………                     
Pregnant…………...                
Breastfeeding……...        
Other………………..                    
  - specify: 
Smoking habit 
Current smoker< 10 cpd……..          
Current smoker >= 10 cpd…..       
Ex-smoker >= 5 years………..             
Ex-smoker < 5 years…………               
Never smoked………………...                         
Unknown………………………                                 
Smoking advise given:    Y or N 
  - specify: 
 
 
Date of first visit 
No of clinic visits 
Referral BP 
Target BP 
BP final visit 
Family history 
Diabetes      Cardiovascular disease   
 
Other: 
 - specify 
 
Alcohol consumption 
(Limit 21 units men, 14 units 
women/week) 
Within limit (F/M)……………...                      
Excess limit (F/M)…………….                    
No alcohol……………………..                                
Unknown……………………….                                                                
Advice given:   Y / N / unknown 

















    - specify: 
 
Medication checked and verified by: (please circle) 
SCI-DC   GP letter   GP practice   Patient   Patients own drugs   Repeat prescription 
 
Other: 











EDUCATIONAL NEEDS ASSESSMENT 








Oral agent timing……. 
Missed doses………... 









RELEVANT MEDICAL HISTORY 
Cardiovascular  date   date  date Diabetes 
Type 1       
Type 2       
 
Date: 
Hypertension ……...   
Angioplasty…………      
IHD………………….                  
 Stroke/TIA…...    
MI…………….                
PVD………….                   
  Angina………..          
CABG…………            
Other………….             
   - specify 
Other/comments: 
RELEVANT  DIABETES TREATMENT (PAST AND CURRENT) 
Start 
date  





        
        
        
        
CARDIOVASCULAR MEDICINES (antihypertensives, lipid lowering agents, antiplatelet agents) 
Start 
date  





        
        
        
        
        
        
        
        
        
        
OTHER RELEVANT MEDICINES (including OTC) 
Start 
date  





        
        
        
        
LABORATORY INVESTIGATIONS 
 Date          
eGFR (/1.73 m2)          
Creat (55-150 µmol/l)          
Urea (2.5-6.6 mmol/l)          
Urine ACR          
Na (132-144 mmol/l)          









HbA1c (<7 %)          
Total chol           
HDL           
LDL (< 2 mmol/l)          





Total/HDL (<4 mmol)          
ALT (10-40 u/l)          
ALB (36-47 g/l)          





GGT (5-35 u/l)          
Blood pressure (mmHg)          
          
          
           
# Clinic 
visit  


























































      
IDENTIFIED CARE ISSUES 
Appendix 6: FOCUS GROUP TRANSCRIPTION 
“How do you think the result reflect what you do in practice?” 
“I think from what Carol was saying about the recording in SCI-DC, we would… I know I change the 
drug from SCI-DC, but I don’t always say that in my notes care plan, cause you do it, and you say 
increase dose and then you go and make it in SCI-DC, but you then don’t go back and say: changed it 
in SCI-DC, because you already said dose changed” (Pharmacist 1) “We are maybe not recording 
stuff like we actually should do. I always do, I do aside of my list clinic, to see what they have done, 
but it’s not in the care plan it’s in my clinic letter. I use my memory; but you know you gonna” 
(Pharmacist 2) “Yeah yeah”(Pharmacist 3) “Yeah, but when you change it in SCI -DC, if it’s a start 
date and a finish date and you are changing the dose, then you can do that, and then you can work 
out from SCI-DC who’s changed it when” (Pharmacist 1) “Exactly, that’s the same how its working for 
my care plan, but maybe we are not making it clear enough” (Pharmacist 2) “Yeah” (all) “I know 
certainly from the time I spent with Ingrid, the thing with me is I don’t write down enough of what I say. 
Because I mean I’m not- I’m doing it, but it’s not clear enough that I’m doing it… (…)” (Pharmacist 2) 
“Is that detail or is it specific?” (Pharmacist 3) “A sheet thing, was like, you know like, I suppose that 
we got the tic boxes that for, but maybe using them better. You know discussed diet, exercise and 
keep it as a mind keeper” (Pharmacist 2) “Because you take it a bit distracted” (Pharmacist 2) “And I 
sometime like to take a note for next week, if I’ve missed one thing, for next week” (Pharmacist 2). 
“And also if seeing patients notes, sometimes you don’t write everything in your own notes, but when 
your dictating the letter. You know it’s gonna be in the letter, so if, you know, when we are seeing our 
patient we are not just reading our own notes, we are also reading…I’ll also check what I wrote the last 
time, you know cause that’s a reminder for me” (Pharmacist 1) “Yeah, so do I” (Pharmacist 2) “And 
then we wouldn’t checks the patient note letter, but we would just go on what we put there” 
(Pharmacist 1) “ I suppose there’s an argument there for actually putting our care plans in the notes, or 
a version of them that you are looking at. In supplementary prescribing or independent prescribing…in 
supplementary you have to have clinical management plan in the notes. Independent, not necessarily, 
but you know, you have to have your documentation in there” (Pharmacist 4) “Actually I don’t like that 
with my notes, because I (…) (Pharmacist 2) “But that’s what we thought now, to actually have a 
paper” (Pharmacist 4) “yeah, so that would maybe be the right (…)to put stuff in”(Pharmacist 2) “Yeah, 
but if you did that and then you didn’t get the case notes, and you put all your guts away” (Pharmacist 
1) ”Yeah, that’s an understanding thing, you know what, I can see where it would be beneficial, but 
often(…)”(Pharmacist 2) “Or you could enter in directly into SCI-DC, that would be lovely” (Pharmacist 
4) (…) “Why don’t we just write into patients notes? Your not using…have still have our own stuff, but 
you know, you just take blood pressure, cholesterol level, and just do like what the doctors. So it’s a 
visit… (Pharmacist 1) “No, no, you can’t do both” (unknown) “Well, we could make a pro-forma which 
could go in, I don't think you’ve seen the documentation of the use of the cardiovascular risk clinic. 
Called the (….) which is not unlike ours, with a lot of tic boxes on it. And, you know, they have things 
like, diet and cholesterol recorded etc, and then treatment recommendations. And that would’ve been 
(…) But, I think there is also (…) (Pharmacist 4) (…)(20 sec) “In another form, and keep your own 
notes” (Pharmacist 5) “Sometimes to write stuff is laborious. But, I do love (…) I do the care plan and 
the recommendations, and then I do (…) A, because I have the letters. So I use SCI-DC for that 
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purpose too. And then I write the out-patients notes…, because if the doctor is seeing in between time 
my letters wouldn’t be typed up, or what ever, so I just put the brief thing in the…” (Pharmacist 3) (…) 
“I think I do that just for the out-patients, I don’t (…)”(Pharmacist 1) (…) “I do the letter, the out-patient 
letter and I do the SCI-DC” (Pharmacist 3) (…) “We all do the three, the GP letter, our own notes and 
SCI-DC” (Pharmacist 4) (…). 
 
“Do you think this kind of audit is relevant for your practice?” 
“It’s interesting that the areas that we don’t seem to contribute are: Like two, like your high number are 
very much higher than your low numbers, if you see what I mean. So... you maybe tick, and then there 
is areas that…do you know what I mean? Whether we are not touching on it or whether it is not 
necessary or…” (Pharmacist 2)” Or if it’s not documented, and that’s the numbers of record of drug 
history” (Pharmacist 5)” We’re doing that, but we are not documenting it (Pharmacist 2 and 5) “The 
healthcare team members’ education/information, we’re doing that to” (Pharmacist 1) “So, what is that 
about, Ingrid?” (Pharmacist 2) “To the doctors or the DSN, and the (…) you talk about what is 
recommended for a particular patient” (Pharmacist 1) “Is for example their giving advise on drug 
formularies and such, but that’s maybe much more in hospital wards I think” (researcher)”That’s just 
maybe something that we just…” (Pharmacist 2) “Something, there have been cases where by a GP 
(…) bendrofluazide 5 mg, and who I kind of interesting actually, you know (…), and there might be 
metabolic issues with it. Something that could run by talking to…so its not, so that’s a medication thing 
like in the letter, rather in the care notes. And then you put, you know, bendrofluazide 5 mg 
explanation mark, in my care plan, and that’s all it means. Ehm, but I don’t know if you would do that 
about (…) put it in the care plan” (Pharmacist 3) “Or I would just say, dictate the letter, and send a 
copy to the dietician. So, you know, that wouldn’t necessarily be recording that” (Pharmacist 1) (…)(23 
sec) “The thing is I’m having more problems with the compliance inquiries illuming, because a huge 
part of the patients don’t know what their taking. And unless they bring in their medicine…there 
actually (…) having complications I think, I would have to look it over (…) I’m going to ask them to 
bring them in (…) That should be quite interesting, but the whole interaction is based on the quality of 
everything of what their taking, and why (…) taking”(Pharmacist 3) “And if that’s wrong, then…” 
(Pharmacist 2) “…(…) to my mind, the record, SCI-DC etc (…) what people are on, what they...(…) 
her blood pressure was really high, she’s on everything, and it looks like she got 8 mg, but her 
daughter filled the dosett box… and I send an extra letter to her daughter, because I’m not completely 
convinced on the treatment she had  been on. And the daughter phones me up, and she says my 
mum’s doxazosin was stopped at Christmastime, and I said (…) and her metformin was stopped at 
Christmastime, because her GFR had been off, and we stopped that. But we had not stopped the 
doxazosin. We didn’t know, the GP had done it and had not informed us. So here was me saying I’ll 
put it up to 12 mg, and that was because I thought she was on 8 mg already. And, luckily she phoned 
me, so we could start with 4. But otherwise, I manage my patients completely wrong (…)” (Pharmacist 
3) “ That is the thing, you’re purely relying on the information (...) But I tend to do a (…) dribbling on 
the notes…yeah you know different colours” (Pharmacist 2) “Relying on SCI-DC being up to date” 
(Pharmacist 5) “You could get them from GPASS and should be up to date” (Pharmacist 2) “I think 
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they should carry a bag” (Unknown) ”You see I went through the united care summary” (Pharmacist 1) 
“You see I can’t. And the other thing is, you remember how X was talking about two types of SCI-DC, 
clinical and (…). But in Roodland I think I use the clinical one. Is that updated through GPASS?” 
(Pharmacist 3) ”Their both (…) directly in relation, except for patient specific (…) for apparently there is 
no interface with those (…) “(Pharmacist 4) (…) “And there are (…) who are still looking for that 
consistency. Not many, but there are a few” (Pharmacist 4) (…) “That would be on clinical SCI-DC, 
clinical” (Pharmacist 4) “But, I could go in from the hospital and (…) summary box” (Pharmacist 5)”I 
get the full (…) from the GP surgery” (Pharmacist 5) (…) “And that’s good, but it’s got wee, it’s got 
limitations, because a part of the acute things that it’s got on there, are not so up to date, so again (…) 
maybe extending that, there would be limitations but again (…)” (Pharmacist 3) “But at St.John`s you 
are on clinical infirm, you’re not..?” (Pharmacist 4) “Yeah” (Pharmacist 5) “So you got both” 
(Pharmacist 4) “I only always do a (medication review) if they bring their tablets, because like you 
(Pharmacist 3), I just don’t trust them” (Pharmacist 1) (…) “Next time, bring your tablets. All my 
tablets? Yes, all your tablets. And we’ll go through. And then I get them to say, what’s that for, what’s 
that for? How do you take it? And that’s how I find out if what their taking and if they know what it’s for. 
And if they say: Oh, my daughter fills it. And I say: Well, can your daughter come in next 
time?”(Pharmacist 1) “So I think that something that we could probably build on and improve the 
problem” (Pharmacist 3) “I think that should (…) I don’t know what your invite letters like. But I think in 
my it says to bring your repeat prescription (…)” (Pharmacist 3) (…) “Bring in all your tablets AND your 
repeat prescription form if you got it” (Pharmacist 4) (…)(33 sec). 
 
“Do you think this might help in the argument for pharmacist-led clinics rather than nurse led 
clinics?” 
“You would have to do a comparison then” (Pharmacist 3) (…)(21 sec) “I think in published though, 
that I’m aware of in the literature, where nurse-led clinics have actually provided this sort of 
information…” (Pharmacist 4) “They don’t collect that information” (Pharmacist 1) “…most of the 
studies that have been published for nurse-led clinics, for which there are few. Ehm, have just (…) 
improvements in blood pressure and lipids levels etc. So this is where… added benefit of pharmacists” 
(Pharmacist 4) “…(…) contribute, so I think, including the discussion you have had so far, I think a 
strong argument for that could be that (mobile phone ringing)…(…) advantage of looking at 
comorbidities (…) medication review. And a huge part of your contribution would be related to 
medicine. More of knowledge about, even in like the diabetes or cardiovascular risk medicine…in like 
their comorbidities, which have had nurses can be well trained to run their clinics. But they don’t have 
that other knowledge base. And I think that we are in a situation where we’re asked for pharmacist 
management reports of the activity. And, you know, so you don’t have (…) activity. And you don’t have 
it to show (…)” (Pharmacist 6) “Finding it more an advantage” (Pharmacist 3) “Is it clinical pharmacist 
and nurses or pharmacist and doctors? Because, you know, all of the nurses (…) not contributing to, 
but use a lot of medicine (…), which the doctors don’t touch on. So maybe it’s that side of things” 
(Pharmacist 3) “I think there is an argument and the argument has to be there, and the argument has 
to be (…) how do we report that (…)” (Pharmacist 6) “And therefore I think that is what the impression 
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is about. How do this thing (…) help to (…) clinical pharmacist services” (Pharmacist 6) “But I think 
what we said about comparing it to nurses, you know, to promote the role of pharmacist-led clinics we 
need to say pharmacist do X, Y and Z and nurses actually do X. And you would get more value for 
money. But there would have to be a comparison  which you could use to say, well this is the 
parameters we have measured and in a previous nurse study, this is what we measured 
therefore…you are getting more value for money” (Pharmacist 1) “And you think that would be an 
ethical study to do?” (Pharmacist 6) “No, I don’t think we would actually do the study. I think we would 
actually look at, do a retrospective or whatever you call them. You know go back in the papers and 
see who’s done what. And compare what nurses measured…” (Pharmacist 1) “So, what you’re saying 
then is that there’s an argument for auditing your practice?” (Pharmacist 6) (…) “There has to be” 
(Pharmacist 3) “But that why we don’t do that as clinical pharmacists (…) we’re not promoting our 
success. To say, when you actually look at that… But that’s probably because we let our self down. 
And we’re quite good at recording them. And we don’t say, but I have never checked that and that. I’m 
coming from a community pharmacy (…) do the work…In the end of the day you count and the 
prescriptions and that’s all you’ve got (…) it’s getting there, but in clinical setting you don’t have an 
excuse, you do have the time, you do have (…), and you do have…(…).You see I find it very 
interesting to spend time with Ingrid, because she’s like: did you ask her about that?” (Pharmacist 3) 
“Yes, of course you did, but…” (Pharmacist 3) “Getting in to that, you see in my mind it can be 
interesting twice, the things you are doing, but maybe not recording” (Pharmacist 3) “When it comes to 
justification to service as well, you know nurse-led clinics are so prolific and nurses are cheaper than 
pharmacist basically. And (…) multiskilled as well, you know, that we are in danger of loosing our 
place as health care professionals. And our added value a (…) how do you demonstrate that, how do 
you justify your spot, when it comes to services form like (…) which have got a final budget, that is 
clearly important” (Pharmacist 4) “It is interesting, when the doctors see their patients in GP practices 
(…) and check their HbA1c, you know, and they’ve got ten, 15 minutes. A medication discussion can’t 
be done in that time, we need a lot longer” (Pharmacist 5) “I think (Pharmacist 3) might be right, the 
comparison should be perhaps with the doctors, you know, rather than nurses” (Pharmacist 1) “I don’t 
know, I think it is unfair for me to have to compare, we’re constantly having to justify our position, but 
nurses don't have to justify their position, doctors don’t have to justify their position (…)” (Pharmacist 
3) “Frustrates me a bit, the numbers isn’t, because there are an awful lot more nurses out there than 
pharmacists” (Pharmacist 4) “Yeah, of course” (Pharmacist 3) “And also traditionally doctors have 
always run clinics, you know, you go to your GP and measure your blood pressure. So there has not 
been a need to justify (…)” (Pharmacist 4) “yeah, the other thing is nurses have always been based at 
GP practices” (Pharmacist 3 and 4) (…) “ …(…) goes by the population which we can pull” 
(Pharmacist 1) “I think that’s changed (…) I don’t think that’s so much now, I mean certainly all 
together  (…) where I work. You get a various set of people (…) the pharmacist is kind of the first 
health care profession you would go to. And that would change (…)” (Pharmacist 3) (…)(31 sec) “So 
its about, you don’t want to make, you don’t want to record so much that you are not actually (…) so its 
got to be useful and functional, but its got to be slick. And then there is the other side of; should we do 
it all the time or should we do it periodically. You know again, if you do it all the time and people get 
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tired and they are not good at filling in and all that. But if you actually want a good data collection do it 
for a (…) period. So it’s a case of again, how do you want your(…)” (Pharmacist 3) “And also can you 
do it, within using, you know, the people we are actually (…) service documentation, periodically, or 
people like Ingrid coming in. But then she had difficulties because we were not documenting” 
(Pharmacist 4) “She couldn’t read mine” (Pharmacist 1) (…) “But we are trying to do that, to go back 
to, publishing nature, we are trying to that on top of seeing our patients. You know cause, we only get 
paid to do the clinics, so if they here then say…I’m not, cause for the doctors its part of their job. You 
know, they see the patients, then they do the research, and its all, they are there for the whole week. 
So we are there for like, what, four hours. So I think we should be publishing that, its really really 
important, but its not (…)” (Pharmacist 1) (…) “it is not because we don’t value our job, its not because 
we are not thankful, we’re gonna have (…) that’s fine, that’s fine, here are our time to do that, so you 
know(…)” (Pharmacist 1) “if we make it a priority, we just have to attach it in to the service, and then 
(…)” (Pharmacist 4) 
 
 “How valuable do you think it is documenting your contribution to pharmaceutical care?” 
“If you don’t document it, then it’s pointless so, then…” (Pharmacist 3) “I think its valuable, but do we 
want to temper that with not over burden (…) contribution” (Pharmacist 3) (…) 
 
“What is your opinion on how this system of auditing pharmaceutical care from the different 
clinics provides a measure of consistent practice?” 
 “For me it seem that, that we are sort of probably in fact that maybe… the care is quite consistent, but 
we are maybe not, because we are not recording it, we maybe can’t see as much of the consistency 
that are actually happening (…)” (Pharmacist 3) “We are not documenting it all, not (…)” (Pharmacist 
5) “But I think (…) I suppose we should” (Pharmacist 3) “But lot of the variations are depending on the 
practical use (…) much of the difference in the way that, you know, the questions that I ask my 
patients, which come from an ethnic minority background. So the questions are different from the non-
ethnic minorities” (Pharmacist 1) “Yeah, but at the end of the day (…)” (Unknown). “But then again, 
you could equally say that within (a patient group) (…) you have different questioning, so how much 
that actually acceptance to your recorded pharmaceutical care issues, I don’t know. You know what I 
mean, the way to get there may be different, the approach (…) the care issues maybe not that 
different” (Pharmacist 3) “I suppose there is an issue there of providing consistent (…) we’re in a 
service to (…) able to demonstrate that value (…) and yet the clinical outcome such as blood pressure 
and lipids and such…but we actually do what we are doing. And I think, your (Pharmacist 1) clinic is 
slightly different, but again the same standard” (Pharmacist 4) “Yeah, probably” (Pharmacist 1) “And 
this method provides, that Ingrid (…) makes out of what pharmaceutical care, how does it work. Where 
as, the only other way you could do it…it would be quite difficult to use if you were not documenting. 
You were having to make assumptions based on what you could see and what you thought was going 
on…Ehm…so that might be a bit of a problem with it. The other way of doing it would be for us to, as 
we go along; categorise, but then again there is inter-partial variation of what we think…” (Pharmacist 
3) “Yeah, but we could get that through peer review, can’t you? Periodically, we could say, take ten of 
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our care issues…how would you categorise that in your clinic? And then we would gradually get to a 
system where we all work (…)” (Pharmacist 4) (…)(36 sec) “…an audit a few years ago of prescribing, 
of the actual prescribing within the Diabetic clinic, and she came up with some interesting things. You 
could actually look at which of the doctors (…) were not using as much ACE-inhibitors than others 
(…)(33 sec) “Do you think that if we work, you have been involved in Ingrid’s discussion about 
pharmaceutical care issues…got together to agree Ingrid’s project, you know (…) not change it, but it 
interesting to think the categories aren’t, you know, what we are doing. I think a change, and because 
of doing that, it is directly (…) of what (pharmacist 6 said), what should we do exactly to fit our 
purpose” (Pharmacist 5) (…) “I think if you are aware of the need to document, then your probably in 
most cases to do so within your time constrain in the clinic. And I think Ingrid’s project has 
demonstrated quite now, that there is a need to document effort over clinical outcomes…” (Pharmacist 
4)” “yeah, yeah” (unknown) “And then the follow-up, that would be we actually do something with the 
results (…)” (Pharmacist 4) “Documenting…that changes your practice” (Pharmacist 5) (…)(20 sec) 
“…(…) and running through that in (…) so now I put my boxes and then I check them and then I go 
through the care plan …(…) but I go through it” (Pharmacist 3) “That was the whole point of that care 
plan, to actually make sure that everybody was basically following the treatment guidelines to help 
you” (Pharmacist 4) (…)(19 sec) “The first time I see them I …(…)” (Pharmacist 3) “That could just like 
be that you would be able to document your pharmaceutical care issues then as you go, as you go 
along” (Pharmacist 4) “Ehm, it depends on lot of mine I wouldn’t be sure before after speaking to my 
doc. So that what I do at the clinic, and then I am under pressure to get my letters signed, SCI-DC etc 
so…realistically, I guess if I had time prior to my next clinic, I could do that then when reviewing my 
patient (…)” (Pharmacist 3) “Maybe there is a way of looking at the key, common care issues, coding 
them and having them on each care plan, so that you are just ticking it  (…) so that there’s not very 
labour intense kind thing” (Pharmacist 4) (…)(30 sec). “The only other think would be…you know that 
(…) intervention form. You know to record…so that’s kind of a (…) it could be in the 
patient…(…)…you could just go through”(Pharmacist 3) “That might work” (Pharmacist 4) (…) “First 
visit we have so much taking up with (…) and the number of (…) and then they are not interested in 
talking about (…) I mean their not…(…) more time in the second visit” (Pharmacist 5) (…)(17 sec). 
 
Database assessment tool 
(…)(24 sec) “It’s quite different to the one that (Mr X) produced, if you remember, it had a quite user 
friendly approach, where you basically filled in in a (…). This is more like a traditional database” 
(Pharmacist 4) (…)(3 min 10 sec) “What is the point?” (Pharmacist 1) “Well, that is what we need to 
decide really…Ehm… ideally, we obviously, its time to input” (Pharmacist 4) “But, that’s perfect” 
(Pharmacist 3) “Its very comprehensive…(…)”(Pharmacist 4) “…(…) SCI-DC to that 
format”(Pharmacist 3) (…)(34 sec). “I think ideally, this would fit on SCI-DC, so it would just be to sit in 
your clinic room and enter the data once. Its much more of an issue if you are having to, I mean, at the 
moment we have basically an excel spreadsheet, which we enter data into periodically. And this could 
fill our (…) if it was possible to email it around so that we could…(…) so that you then put in all your 
stuff, but actually to complete that is much more labour intensive than an excel spreadsheet” 
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(Pharmacist 4) “And who else could have access to it? If you go to SCI-DC, you know who the last 
person was that following that patient. Another clinician check to see, oh I wonder what the pharmacist 
did? So you know, you still have to go to SCI-DC to do patients visits,  so that it is recorded, but that 
you actually saw them (…)”(Pharmacist 1) (…) “That could be like a drop down or something, where 
the pharmacist activity form”(Pharmacist 4) (…)(44 sec). “(…) you are ahead of that with SCI-DC with 
an electronic system, but the secret is, you can’t use that in an electronic system..(…) what can I do, 
and what you actually want, and what you want to record, what you want to record of activity in a 
paper system and then get that in…” (Pharmacist 6) “Yeah, care planning” (Pharmacist 3) “I think this 
is excellent (…)” (Pharmacist 6) “I think we should try it though (…) for SCI or a connection for SCI (…) 
” (Pharmacist 5) “You mean, bring it down to a minimum?”(Pharmacist 4) (…) “You think it (…)…it 
could be a…we talk about just using this as a first visit and final visit. It would be interesting to use it as 
an up to date database, it surly is (…)” (Pharmacist 3) (…). “Recording first and after if it’s a new 
patient. And then after that it could (…)”(Pharmacist 2) “There has to be a link to SCI-DC, because if 
we are doing a change in the medication…(…)”(Pharmacist 1) “The problem with SCI-DC is that the 
field (…) we only know what they are currently on, so there’s no reference on the history (…) I think 
that’s a good point (…) and ideally we would have it interfacing with SCI-DC”(Pharmacist 4) “(…) other  
healthcare professionals need to have access to what we are doing, because if they are currently 
unaware of what we are doing, then they need to be able to see what we are doing. And if they don’t 
have access to our paper notes (…)” (Pharmacist 1) “(…) Pharmaceutical care is not what the 
pharmacist does (…)” (Pharmacist 6) “So would they (other healthcare professionals) contribute to this 
then?” (Pharmacist 1) “Yes” (Pharmacist 6) “What, do they currently complete anything electronically 
in SCI-DC the nurses? I know the dieticians, but…in the clinic (…)…but I don’t know about the nurses 
if they put anything on. All I ever see in case notes is their hand written (…) you know, altered their 
insulin (…)” (Pharmacist 4) (…) “the podiatrist do nothing, there’s not anything in the notes, there’s 
nothing electronic. And the retinal screeners with the reports on their eyes (…) that’s it” (Pharmacist 4) 
(…)(1 min 13 sec) “As regards Ingrid’s project are you planning on entering all these care issue into 
the database?”(Pharmacist 4) “I have entered all the care issues” (Researcher) “You have that, you’ve 
done that. So we are in a situation where we could actually print out reports” (Pharmacist 4) (…) “So 
we know that its functional (…)” (Pharmacist 3) “It works well obviously, but it’s how it going to work in 
practice (…)” (Pharmacist 3) (…)(18 sec) “..(…) so, you know kind of say like: we haven’t been doing 
this, and how can we achieve it in clinic?” (Pharmacist 2) (…) “In order that pharmaceutical care 
issues that we tick, we could actually get our paper versions, do it, say another person who could then 
enter them all in, and he or she could then put it all in this database and drop all the graphs for us. 
Rather than us doing all the time”(Pharmacist 1) “But if the format is appropriate…(…)” (Pharmacist 3) 
(…)(56 sec) “Its easy to write when the patients are there, because I can look at them and write on it 
all the time, but you can’t type and look at …(…)” (Pharmacist 1) (…) “We could actually just have it 
the care plan, couldn’t you, and then have the category…(…)…because you know who your patient 
is…(…)” (Pharmacist 3) “You know eventually, ultimately, if we had hand held pad instead of a care 
plan we could just dot in the details…and it all enters in to a database…”(Pharmacist 4) (…)(43 sec). 
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“Has what I have presented prompted you to change your practice?” 
“Yes, I think so” (Pharmacist 2) “I think we need to look at (…) what we are doing and how we are 
auditing and how we would want to be auditing” (Pharmacist 4) “And if we are auditing, who would we 
report back to?” (Pharmacist 3) “You know if we are doing things that you really want to inform 
to…what forum would be interesting to (…)”(Pharmacist 3) “As a member of the Pharmacy clinical 
management team, I can tell you that (…) monthly reports (…) So X and Y have been looking at 
indicators (…) opportunity to input to that (…) its quite minimal at the moment, but I think it needs that 
basic level, because it needs to be developed and it needs to be developed (…)  and what the line that 
we need. Everyone is used to their own practice (…) database (…) in terms of planning, because if 
(…) argument there for terms of the patients’ pharmaceutical needs. So if you got information about 
patients’ pharmaceutical needs, then it’s far easier to (…) argument for (…) required to meet these 
needs. So you need to (…)(26 sec)“ (Pharmacist 6) ”(...) before we rush in to what format , I think, 
there is no point in developing a system that’s not in the appropriate format” (Pharmacist 3) “Well, I 
think (…) say: we have provided this database for our practice, this is the reports that we believe 
demonstrates (…) and therefore we would want that (…)” (Pharmacist 6) (…)(14 sec) “NHSScotland 
has to meet the Heat Act, you know about the Heat Act? (…)(26 sec)” (Pharmacist 6) “From my 
understanding its that the Government is looking for a reduction in the number of anti (…) prescribed. 
You know, we are not recording…you know…we say “drug stopped”, you know, but we’re not auditing 
that. So if we want to show our usefulness to the Government, in financial terms, we should be able to 
say: “We stopped doxazosin (…) some of the patients and we saved so much money. Because that 
what we are, although we are meeting Heat targets, we are also looking at (…)” (Pharmacist 1) (…)(1 
min 28 sec) “ I’ll certainly contact X about what indicators (…) something like safety, that’s an obvious 
one. And that we could easily construct from our figures now – patient safety (…) you know yourself 
there are so many incidences on a daily basis, where patients doses has to be reduced or adverse 
effects or you know (…)” (Pharmacist 4) (…) “(…) we’re not employed by NHS Lothian, so we 
(community pharmacies) are different in that perspective, you know its not money blown by NHS 
Lothian, but the thing is we are probably the biggest single force that prevent medication 
errors…contacting GP`s, reducing these problems…and we are not accountable to anybody, and we 
don’t have to show to anybody. As long as (…) not loosing his money (…)” (Pharmacist 2) (…)(20 sec) 
“(…)how to show benefit from what we document (…)” (Pharmacist 5) (…) “And still after 30 odd 
years, we still haven’t decided what to document” (Pharmacist 5) (…) “Outcomes of what our 
interventions are,  clinical outcomes (…)” (Pharmacist 3) (…) “(…)all the time… forget to do, but you 
document after a week” (unknown) “You write down every single ting, bit you miss that huge 
intervention action thinking (…)” (Pharmacist 5) (…) “Should we document everything or should we 
just document interventions” (Pharmacist 5) “If you can do it on a paper, in a short hand way, in a 
pretty standardised thing, which can then be made electronic…then you got (…) in a database that 
Ingrid has developed. You have reports for who ever is asking for reports, if it’s for your self for your 
own practice…being for management (…) but if you got your information there (…) developed a 
database that could do that (…)” (Pharmacist 6)   
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You are invited to participate in a focus group discussion regarding the finding from 
my audit at three of the DCVR clinics. The meeting will be held on the 30th of April at 
1.00 pm in Seminar Room 2, Chancellors Building, RIE.  
 
My name is Ingrid Lian and I am a Norwegian pharmacy student in my final year. I 
am doing my project here in Scotland in collaboration with the University of 
Strathclyde. With the help of Alison Cockburn I have conducted a project to try and 
evaluate the pharmaceutical care delivered in the clinics and also worked on making 
a database to be used to standardise the recording of achievement of outcomes. 
Now I am interested to find out your point of views. The meeting is supposed to be an 
open discussion amongst you – I want to know what you think, both good and bad. 
 
I would like to tape-record the discussion and also take notes, because I don’t want 
to miss any of your comments, and this will help me when I am going to analyse the 
results. I will of course keep everything you say anonymous and therefore not use 
any names in my report. The results will be included in my thesis that I will submit to 




• Presentation of the findings from the audit and discussion 
• Review of the database as an assessment tool 
• The use of a standardised pharmaceutical care plan 
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Recent clinical trials have clearly demonstrated that aggressive treatment of  
hypertension and hyperlipidaemia can result in a substantial reduction in 
cardiovascular events in patients with diabetes.1 Consequently pharmacist-led 
diabetes cardiovascular risk reduction clinics (DCVR) have been established within 
both primary and secondary care sites in NHS Lothian during the past 3 years. 
 
These have achieved significant reductions in patients’ blood pressures (average 
reduction of 35 ±18mmHG systolic and 16 ±12mm Hg diastolic) and improved lipid 
profiles. Improvements in patient’s blood pressure and lipid levels are achieved via 
treatment recommendations made to GP’s, provision of advice on smoking cessation, 
diet and exercise and optimisation of patient compliance with their medications.2 
 
There is limited published work on pharmaceutical care systems and therefore there 
is a need for testing suitably designed models of pharmaceutical care in particular 
patient groups such as those with diabetes.3  Previous work within oncology has 
shown that development of a pharmaceutical care plan has standardised the 
provision of pharmaceutical care to patients receiving chemotherapy.4  Studies of 
pharmaceutical care activities performed by the clinic pharmacist at one site in 
Lothian resulted in production of a pharmaceutical care plan incorporating evidence-
based guidelines.5  This has now been implemented at all the sites and there is now 
a need for continuous audit of practice and a method of reporting pharmaceutical 




To evaluate practice within pharmacist-led Diabetes Cardiovascular Risk clinics from 
implementation of a standardised pharmaceutical care plan and develop a tool for 
reporting pharmaceutical care needs and activities. The tool will be applicable to 





1. Review the literature on models of pharmaceutical care to patients with 
diabetes. Review documentation from local services to characterise service 
provision in hospital and primary care settings. 
 
2. Develop and populate a database using pharmaceutical care data from 
several sites to quantify the pharmaceutical care issues addressed by the 
pharmacists and to standardise the recording of achievement of outcomes. 
Ensure that the database is suitable for recording data from pharmacist-led 
Diabetes Management clinics and Diabetes Cardiovascular Risk clinics. 
Extend the audit to include patients sampled from other participating sites. 
 
3. Receive feedback from a focus group of the DCVR clinic pharmacists to 
identify opportunities to standardise the approach of the pharmacist and 





Subjects and Settings 
 
Patients will be recruited retrospectively and prospectively from the following clinical 
settings/pharmaceutical care providers 
 
Table 1: Overview of patient care settings, pharmacists and patient sample 
 
Patient  Care Setting 
 
Pharmacist (s) Patient 
sample 
A 
Diabetes Cardiovascular Risk 
Clinic Western General 
Hospital 
Alison Cockburn 30 
B Diabetes Cardiovascular Risk 
Clinic Royal Infirmary  
Juliette Rose 30 
C Diabetes Cardiovascular Risk 




D Diabetes Cardiovascular Risk 
Clinic Roodlands 
Carol Philip 10 
E Diabetes Cardiovascular Risk 
Clinic Leith (including Ethnic 
Minorities Clinic) 
Lubna Kerr 30 
F Wester Hailes Medical Centre Pauline Westwood 
 
10 
G Colinton Health Centre Ian Brown 
 
10 
H Blackhall Medical Centre Alpana Mair 
 
10 
    
 
 Patient protection of privacy and confidentiality will be maintained by giving each 
patient a chronological number as they are enrolled in the study. The patient 
numbers will be kept together with any identifiable patient information in a physically 
secure place.  
 
Protocol will be approved by University of Tromsø in collaboration with University of 
Strathclyde, NHS Lothian Research and Development Department and the Director 








1. A literature review will be performed to identify models of pharmaceutical care 
used for patients with diabetes including local service provision in primary and 
secondary care. This will be done by: 
I. Conducting a literature review using Medline and Embase 
II. Contact other pharmacists, by e-mail, who run similar diabetes or DCVR 
clinics outside Lothian, to obtain other pharmaceutical care plans to be 
reviewed. 
III. Reviewing previous projects undertaken in this field  
 
2. A prospective and retrospective audit of pharmaceutical care activities 
undertaken at sites A, B and E (table 1) will be completed. If necessary patient 
data will be gathered retrospectively from participating sites. To execute the 
audit the researcher will: 
I. Develop a draft data collection form which will be used to collect patient 
data and pharmaceutical activities. The form will be based on available 
pharmaceutical care plans, findings from the literature review and the 
data fields in the database. 
II. The final data collection form will be decided together with the rest of the 
research group to achieve face validity and field tested on a few number 
of patients. Any necessary changes to the data collection form will be 
done after the field testing. 
III. Attend the different clinics to collect data. This will enable the researcher 
to observe and to discuss with the pharmacist what changes that have 
been done. The data collected will then be based on actual events and 
not on the views and memory of individuals. Any available data on the 
patients will be recorded on the data collection form prior to the clinic 
visit, with the aid of   SCI-DC, Apex, patient case notes and 
pharmaceutical care plans. 
IV. Categorise care issues identified by the pharmacist during the clinic visit 
and care issues documented in the pharmaceutical care plans. The 
categorisation of the care issues will be described and categorised using 
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an international classification of actual and potential drug therapy 
problems.6 Pharmaceutical care activity will be documented as either 
checks or changes.7  
V. A database, incorporating the activities from the audit and data from 
other participating sites, will be developed. The database will: 
 
- Be based on previous databases developed in this field. The assessment tool will 
be remodelled to fit the pharmacists’ practical needs. 
- Comprise essential data fields from both pharmacist-led Diabetes Management 
clinics and Diabetes Cardiovascular Risk clinics.  
-  Include more comprehensive data fields associated with ethnic minorities.   
- Be used to generate reports of the pharmaceutical care provided to diabetes 
patients, eg. comparison of different groups of patients, comparison of different 
clinical settings etc. 
VI. Categorise each care issue according to which guideline standard in managing of 
cardiovascular disease it is trying to address. The guideline standards used will be 
based on a validated medication assessment tool (MATCVD) developed by PhD 
student Tobias Dreischulte at Strathclyde University, Glasgow. 
 
3. The findings of the audit of pharmaceutical care activities will be reviewed in a 
focus group comprising the DCVR clinic pharmacists. The research group, 
comprising the supervisors and the researcher, will meet half way through the 
data collection to organize an interview schedule for the group interview. The 
time frame will be one hour and a maximum of 10 questions will be presented to 
the group by the researcher. The discussion will be audio recorded with consent 
of the participants and transcribed.  
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Analysis of Findings 
Descriptive statistics will be used to describe the demographics of the sample in 
terms of age, gender, ethnicity, number of clinic attendance, number of medications, 
care issues etc. Each care issue will be categorised as either checks or changes. 
Reports from the database will also be used to compare eg. different groups of 
patients or clinical settings and pharmaceutical care activity.   
 
Focus group outcomes will be identified using content analysis of the audio recorded 
interview. The analysis will generate themes taken up by the DCVR clinic 





1. UKPDS Group (1998) Tight blood pressure control and risk of macrovascular 
and microvascular complications in type 2 diabetes (UKPDS 38). 
BMJ;317:703-713       
2. Cockburn A, Kinnear M, Strachan MWJ, McKnight JA and Lannigan N. Impact 
of a Pharmacist-led Cardiovascular Risk Reduction Clinic on cardiovascular 
risk factor targets in patients with diabetes. Diabetic Medicine 2005;22 supp 
2:62 
3. Tulip S, Campbell D. Evaluating pharmaceutical care in hospitals. Hosp. 
Pharmacist 2001;8:275-79 
4. MacIntyre J, Dalrymple H, MacLean F, Lannigan N and Hudson S. 
Development of a system for reporting pharmaceutical care issues in cancer 
patients receiving chemotherapy. Pharm. J. 2003;271:266-7 
5. Cockburn A, Kinnear M and Warnock CA. Pharmaceutical care needs of 
diabetic patients attending a pharmacist-run cardiovascular risk clinic. Pharm 
World and Science 2007; in press 
6. Charles D. Hepler, Linda M.Strand. Opportunities and responsibilities in 
pharmaceutical care. Am J  Hosp Pharm. 1990; 47:533-43 
7. Hudson S, McAnaw JJ, Johnson BJ. The changing roles of pharmacists in 
society. IeJSME 2007; 1:22-34 
8. Reilly V, Cavanagh M. The clinical and economic impact of a secondary heart 
disease prevention clinic jointly implemented by a practice nurse and 
pharmacist. Pharm World Sci 2003;25:294-8 
9. Reid F, Murray P, Storrie M. Implementation of a pharmacist-led clinic for 







Focus group interview – pharmaceutical care delivery and documentation 
 
Findings from the audit of pharmaceutical care issues 
 
1) How do you think the results reflect what you do in practice? 
• If agreeing – “patient or carer understanding/compliance” (advice on diet, 
exercise, smoking) only 44 times over 186 care episodes. Important part of 
your delivery of pharmaceutical care. Low? Under-documented? 
 
• This only presents what has been documented – do you feel there are 
activities you undertake which are not reflected in the results? 
o If yes – which activities? 
 
• How relevant do you think this kind of audit is for your practice? 
o  Demonstrates risk management activity 
o Assesses pharmaceutical care needs and may help in strategic 
planning of services 
o Shows contribution to pharmaceutical care provided by pharmacists 
 
2) How valuable do you think it is documenting your contribution to pharmaceutical 
care? 
• Do you think this is a good method to measure the process of pharmacists’ 
activities?  
o If no – are there any other ways of reporting pharmacists’ activities? 
o If yes – how so? 
o Do you think it might help the argument for pharmacist led clinics rather 
than nurse-led clinics (in the absence of comparable clinical outcome 
data)? How so? Why not? 
o In other clinical areas (e.g. stroke) the pharmaceutical care plan has 
been developed in tandem with a multidisciplinary integrated care plan. 
What’s the potential for a similar development in your clinics? 
  
• Evidence on patient safety issues – E.g. Patient been to clinic, develops acute 
renal failure next day – need to document what you have done. 
 
• How do you feel that documentation in a standardised care plan would 
facilitate consistent delivery of care across the clinics?  And would also 
support new clinic pharmacists? Would you explain further? 
 
• What are your thoughts about documenting recommendations in a care plan 
for use by community pharmacists?  
o Identifying standard care issues may help develop SCI-DC with 
pharmaceutical care fields to ease information exchange. 
 
• What are your thoughts about the standardised care plan forming the basis of 




3) What is your opinion on how this system of auditing pharmaceutical care from the 
different clinics provides a measure of consistent practice? 
 
Review of the database as a means of generating audit reports  
 
4) At this time the database is a research tool which takes time to populate, but what 
are your thought about the benefits to your practice in using this tool? 
• Benefits – easy to do queries on both clinical outcomes and pharmaceutical 
care delivery 
 
• If it was quick and easy to use, would you use it? 
 





5) Have what I have presented prompted you to change your practice? 
• What is the next step? 
 























Clinical (shared) record of patient characteristics
Clinical (shared) record of drug history
Continuity of information/care between clinical settings
Level of patient monitoring 
Health care team member(s) education/information
Appendix 10: 
 



























































Figure 2. % distribution of documented Change in Drug Therapy Process (n = 211) in 47 patients over 





























































                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
